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1. Summary  
 
 
Adamalysin 19 (a disintegrin and metalloproteinase 19, ADAM19, or meltrin ß) is a plasma 
membrane metalloproteinase. In this dissertation, I revealed that hADAM19 zymogen 
contains two functional furin recognition sites (RXK/RR), R197PRR200 and R200MKR203, 
between its pro- and catalytic - domain by protein N-terminal sequencing, specific furin 
inhibitors, mutagenesis, and furin-deficient mammalian cell lines. R200MKR203 is the primary 
cleavage site, but R197PRR200 is an alternative site for activation when the primary site is 
abolished. Co-localization between furin and hADAM19 is  also identified in the ER/Golgi 
complex and/or the trans-Golgi network. Furthermore, hADAM19 is processed at E586-S587 
within cysteine -rich domain by an autolytic mechanism and the sizes of the side chains of the 
residues at both E 586 and S587 are critical for this processing. This proceesig is necessary for 
hADAM19 to exert its proteolytic activities in vitro as illustrated by mutagenesis, such as 
both E586 to D586 and S587 to T587. Based on this processing, I also developed a flourescamine 
assay to determine the activity of soluble hADAM19 by using a peptide substrate of Ac-
RPLESNV, which is identical to the sequence encompassing the processing site. Interestingly, 
the autolytic processing at E586-S587 occurs intramolecularly, not intermolecularly, produc ing 
an N-terminal fragment associated with its C -terminal fragment through disulfide bonds. The 
cysteine residues at C605 , C633, C639, and C643 within the residual cysteine-rich domain of the 
C-terminal fragment are partially responsible for the covalent association of the C-fragment 
with the N-terminal fragment. A new processing site at at Lys 543-Val544 was identified in 
soluble mutants when these cysteine residues were individually mutated to serine residues. 
These soluble mutated proteins were properly folded and secreted, but were less stable and 
more easily degraded compared with the soluble wild type, as illustrated by trypsin digestion 
and inactive mutant studies, suggesting that the proteolytic activity and the stability of soluble 
hADAM19 may be regulated by the formation of disulfide bonds that include C 605, C633, C639, 
and C643. Moreover, the new processing site resulted from autolytic cleavage and was shown 
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to be independent of the processing at E 586-S587 by utilizing the double mutations E586 to D or 
E346 to A in soluble representative mutants. Correspondingly, shed fragments are detectable in 
the media from MDCK cells stably expressing the full length mutant with C633 to S, but 
neither C643 to S nor the wild type. Finally, the processing or shedding of hADAM19 is 
unaffected by Ilomastat (GM6001), but is obviously enhanced by phorbol-12 myristate 13-
acetate, a protein kinase C activator; however, A23187, a calcium ionphore, or calmodulin 
antagonists, such as calmidazolium (CLM), W7, and trifluoperazine (TFP) blocks or inhibits 
this processing or shedding, indicating the same complex signal pathways may be involved in 
both processing and shedding of hADAM19.  
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2. Introduction  
2.1 The family of ADAM proteins 
     ADAM (A Disintegrin And Metalloprotease), also called MDC (Metalloprotease 
Disintegrin / Cysteine-rich) protein constitute s a large family with 33 members known so 
far. ADAM proteins play important roles in many biological processes involving cell-
surface proteolysis and cell-cell or cell-matrix interactions (Wolfsberg and White 1996, 
Schlondorff and Blobel 1999, Kheradmand and Werb 2002, Seals and Courtneidge 2003). 
Therefore, ADAMs have been implicated in many vital functions during development 
(Rooke et al. 1996, Wolfsberg and White 1996, Peschon et al. 1998, Qi et al. 1999, 
Schlondorff and Blobel 1999, Kheradmand and Werb 2002) and in the pathogenesis of 
cancer (Kuno et al. 1997, Yavari et al. 1998, Iba et al. 1999, Matthews et al. 2000, Sandy 
et al. 2001, Kheradmand and Werb 2002, Seals and Courtneidge 2003), rheumatoid 
arthritis (Tortorella et al. 1999, Sandy and Verscharen. 2001), Alzheimer’s disease 
(Buxbaum et al. 1998, Koike et al. 1999, Anders et al. 2001, Colciaghi et al. 2002, Hooper 
and Turner 2002), asthma and bronc hial hyperresponsiveness (Van Eerdewegh et al. 2002, 
Seals and Courtneidge 2003), and inflammatory responses (Kuno et al. 1997, Sandy et al. 
2000, 2001). Based on the location, this ADAMs family can be divided into two 
subgroups; The bigger group is the type I membrane-bound ADAMs, containing 
prodomain, metalloprotease and disintegrin domains, cysteine-rich domain, EGF-like 
domain, transmembrane domain, and cytoplasmic domain (Wolfsberg and White 1996, 
Blobel 1997, Black and White 1998, Stone et al. 1999, Primakoff and Myles 2000, Seals 
and Courtneidge 2003). The soluble ADAMs constitute the smaller subgroup, including 
soluble alternative splice variants of several membrane-bound ADAMs and ADAM-TS 
containing thrombospondin-like repeats, besides the prodomain, metalloprotease and 
disintegrin domain, cysteine-rich domain (Figure 1.) (Stone et al. 1999, Primakoff and 
Myles 2000, Tang 2001, Seals and Courtneidge 2003, Somerville et al., 2003). 
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Figure  1. The topography of the ADAMs and related metalloproteases. Generalized 
domain structures of the ADAMs, SVMPs, ADAM-TS, and MMP families are shown. Note 
that ADAM-TS family members have a variable number of thrombospondin-like (TS) motifs. 
The MMP shown is of the gelatinase class. Other subclasses of MMPs lack hemopexin -like 
sequences and/or fibronectin type II-like sequences. The subclass of MT-MMPs have 
transmembrane domains and cytoplasmic tails in addition to the domains shown. 
 
2.2 Latency of ADAMs 
 
       The classic cysteine switch mechanism for the latency and activation was originally 
proposed for MMPs (Van Wart and Birkedal-Hansen, 1990) and may be applied for many 
MMPs identified so far with the exception of MMP3, MMP23, and MMP26 (Chen et al. 
1993, Galazka et al. 1996, Pei 1999, Velasco et al. 1999, Pei et al. 2000, Marchenko et al. 
2002, Park et al. 2002).  The conformation of proMMP3, which is different from its mature 
form, and a salt bridge in its precursor might contribute to the latency of the proenzyme (Chen 
et al. 1993, Galazka et al. 1996). The cysteine residue within the corresponding region of 
proMMP23/CA-MMP belongs to the type II membrane anchor, it is unable to coordinate with 
the zinc (II) in the catalytic domain to keep MMP23/CA-MMP latent (Pei 1999, Velasco et al. 
1999, Pei et al. 2000). There is a unique cysteine-switch motif, PH81CGXXD, in the 
prodomain of proMMP-26, even if the conserved cysteine-switch sequence, PR81CGXXD, 
was restored by mutagenesis, the cysteine-switch activation mechanism was not induced 
(Marchenko et al. 2002), and the partial activation by autolysis produced the active forms 
containing this cysteine-switch sequence (Marchenko et al. 2002, Park et al. 2002).  
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      Regarding the ADAM family members, the active ADAMs, such as ADAM1, 8, 9, 10, 12, 
13, 15, 17, 19, 28, and ADAM-TS1, 4, 9, 12, contain a catalytic site consensus sequence 
(HEXXH) in their metalloprotease domains (Lum and Blobel 1997, Lum et al. 1998, Kuno et 
al. 1999, Loechel et al. 1998, 1999, Stone et al. 1999, Tortorella et al. 1999, Milla et al. 1999, 
Vu and Werb 2000, Primakoff and Myles 2000, Howard et al. 2000, 2001, Cal et al. 2001,  
Wei et al. 2001, Zhao et al. 2001, Shirakabe et al. 2001, Lopez-Perez et al. 2001, Guo et al. 
2002, Cao et al. 2002, Gaultier et al. 2002, Schlomann et al. 2002, Kang et al. 2002b, 2002c, 
and submitted, Somerville et al. 2003). They may also have a putative cysteine-switch residue 
in their prodomains to keep them latent as proposed (Figure 2.) (Grams et al. 1993). For 
example, the latency and activation mechanism of ADAM12 is similar to the cysteine switch 
model as proposed for MMPs (Loechel et al. 1999); some ADAMs, such as ADAM9, 15, 17, 
and 19, showed enzyme activity against their substrates only after the ir prodomains were 
removed, suggesting that, at least, the removal of prodomains in these ADAMs is require d for 
their proteolytic activities, resulting in a reasonable speculation that the latency of some 
ADAMs obey the cysteine switch model, although no direct evidence in many ADAMs, 
including ADAM9, 15, 17, and 19, has been provided to support the hypothesis that Cys -zinc 
coordination is required for latency (Lum et al. 1998, Milla et al. 1999, Roghani et al. 1999, 
Kang et al. 2002b).  
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Figure 2.  Cysteine-switch mechanism in a metalloproteinease-disintegrin. 
Metalloproteinases-disintegrins that have a catralytic-site consensus sequence contain an odd-
numbered cysteine residues in their prodomains that has been proposed to function as a 
cysteine switch (Van Wart and Birkedal-Hansen, 1990). The Zn2+ is coordinated by three 
histidines in the catalytic site; the free sulfhydryl group of cysteine residue provides a fourth 
coordination site. This keeps the protease inactive (latent form) until the prodomain is 
removed. The predominant mechanism for the prodomain cleavage is mediated by furin or 
furin-like PCs in the secretory pathway. 
 
2.3 Activation of ADAMs  
      By sequence alignment, two members in the ADAM family, ADAM8 (Yoshida et al. 
1990) and ADAM28 (Howard et al. 2000)  in mice, do not contain the conserved sequence, 
RXK/RR, which is generally cleaved by furin or furin-like proprotein convertases (PCs), in 
the boundary between pro- and metalloprotease- domains. Thus, for the removal of 
prodomains in  ADAM zymogens , two mechanisms have been reported: One is the autoly tic 
mechanism, which was shown in ADAM8 (Schlomann et al. 2002) and ADAM28 (Howard et 
al. 2000), because no processing of prodomains was observed in their inactive forms, in which 
the respective glutamate residue in their metalloproteinase domains was mutated to A or Q. 
The predominant mechanism for the removal of prodomains of ADAMs is mediated by furin  
or furin-like PCs in the secretory pathway. This mechanism has clearly been shown in many 
ADAMs, including ADAM1, 9, 12, 15, 17, 19, ADAM-TS1, 4, 9, 12, using N-terminal 
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sequencing, specific inhibitors of furin, blockers of protein trafficking from ER to Golgi, 
exogenous soluble furin in vitro, furin-deficient cell lines, and mutagenesis at the furin 
recognition site(s), RXK/RR, between the  pro- and catalytic -domains (Lum and Blobel 1997, 
Lum et al. 1998, Loechel et al. 1998, Roghani et al. 1999, Kuno et al. 1999, Schlondorff et al. 
2000, Cal et al. 2001, Guo et al. 2002, Cao et al. 2002, Kang et al. 2002b, Somerville et al., 
2003). However, in some ADAMs, the removal of prodomain alone is not suffic ient to 
activate the zymogens. For example, mature ADAM-TS4, which lacks its prodomain, has to 
be truncated at its C-terminus to display its aggrecanase activity (Guo et al. 2002); Soluble 
hADAM19 cleaved its prodomain by furin has to be processed within its cysteine-rich 
domain, producing an active enzyme shown by both alpha2-M and a peptide substrate assays 
in vitro (Kang et al. 2002c). In another case, the deletion of the prodomain destroys the 
proteolytic activity of ADAM10 (Fahrenholz et al. 2000, Anders et al. 2001). For ADAM12 
and 17, the prodomains are not only an ihibitor of the catalytic domain, but also appear to act 
like a chaperone, facilitating secretion, folding, or both for the ADAM proteins (Milla et al. 
1999, Roghani et al. 1999). In addition, many different mutants interfere with the folding or 
processing of ADAMs, resulting in a lack of proteolytic processing. For instance, the cysteine 
residue replaced with alanine in the prodomain of ADAM9 abolished its prodomain removal 
(Roghani et al. 1999). Both His346 and His350 substitutions with alanines in the 
metalloproteinase domain of mouse ADAM19 abrogated the processing of its prodomain 
(Shirakabe et al. 2001). The L73P mutant of ADAM12 resulted in complete retention of 
ADAM12 in the ER and inhibition of its processing (Cao et al. 2002). The soluble form of 
ADAM13 has never been converted into its mature form, indicating that the transmembrane 
domain, cytoplasmic domain, or both, are indispensable for the processing of the prodomain 
in ADAM13 (Gaultier et al. 2002). The removal of the disintegrin and cysteine-rich domains 
in TACE/ADAM17 resulted in the secretion of mature catalytic domain in association with 
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the precursor (pro) domain, demonstrating the cysteine-rich domain appears to play a role in 
the release of the prodomain (Milla et al. 1999).  
 
2.4 Functions of ADAMs 
       ADAMs have been shown so far to possess four potential functions: proteolysis, cell 
adhesion, cell fusion, and cell signaling. One of the major functions for ADAMs is their 
proteolytic activities, acting as the sheddases responsible for the releasing of many membrane 
proteins, or as the proteinases for the digestion of components in the extracellular matrix or 
other proteins.  Indeed, five ADAMs have been implicated in shedding processes so far. 
ADAM17/TACE, a major sheddase, has a role in the shedding of tumor necrosis factor -alpha 
(TNF-alpha), transforming growth factor-alpha (TGF-alpha), L-selectin, both TNF receptors, 
interleukin-1 receptor II, HER4, Notch, fractalkine, MUC1, TNF related activation-induced 
cytokine (TRANCE), and Collagen XVII. It also acts as a PMA-induced APP alpha-secretase 
(Black et al. 1997, Moss et al. 1997, Hooper et al. 1997, Peschon et al. 1998, Buxbaum et al. 
1998, Lum et al. 1999, Schlondorff and Blobel 1999, Brou et al. 2000, Rio et al. 2000, 
Primakoff and Myles 2000, Blobel 2000, Garton et al. 2001, Kheradmand and Werb 2002, 
Sunnarborg et al. 2002, Franzke et al. 2002, Asai et al. 2003, Seals and Courtneidge 2003, 
Thathiah et al. 2003). ADAM10/KUZ, another major sheddase, is required for Notch 
signaling. It can cleave the Notch ligand Delta, heparin-binding epidermal growth factor (HB-
EGF), TNF-alpha , L1 adhesion molecule, Collagen XVII and ephrin A2 and is an APP alpha-
secretase (Hooper et al. 1997, Pan and Rubin 1997, Qi et al. 1999, Schlondorff and Blobel 
1999, Fahrenholz et al. 2000, Primakoff and Myles 2000, Blobel 2000, Hattori et al. 2000, 
Mechtersheimer et al. 2001, Kheradmand and Werb 2002, Franzke et al. 2002, Asai et al. 
2003, Seals and Courtneidge 2003). ADAM9/MDC9/meltrin gamma is believed to participate 
in the PMA-stimulated shedding of HB-EGF and is able to increase the shedding of Collagen 
XVII, and also can act as an APP alpha -secretase (Izumi et al. 1998, Koike et al. 1999, 
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Franzke et al. 2002, Asai et al. 2003, Seals and Courtneidge 2003). ADAM19/meltrin beta has 
been linked to shedding of the epidermal growth factor receptor ligand beta?type-neuregulins 
?Shirakabe et al. 2001, Seals and Courtneidge 2003?. ADAM12/meltrin alpha?has been shown 
to be responsible for endogenous shedding of HB-EGF in the heart (Asakura et al. 2002, Liao 
2002, Seals and Courtneidge 2003).  
       Regarding the digestion of components of the extracellular matrix, ADAM10 cleaves 
type IV collagen in vitro (Millichip et al. 1998), ADAM15 cleaves type IV collagen and 
gelatin in vitro (Martin et al. 2002), and ADAM13-expressing cells degrade fibronectin 
(Alfandari et al. 2001). For the cleavage of other proteins, ADAM10 has first been shown to 
digest myelin basic protein (MBP) (Chantry et al. 1989), and MBP is also cleaved by 
ADAM8 (Schlomann et al. 2002). The soluble metalloprotease domain of MDC9 cleaves the 
insulin B-chain, a generic protease substrate (Roghani et al. 1999). A soluble ADAM12 exists 
as an alternatively spliced protein, which has been shown to cleave insulin -like growth factor-
binding protein (IGFBP)-3 and -5 (Shi et al. 2000, Loechel et al. 2000). ADAM10 and 
ADAM17 contribute to the constitutive and PMA-regulated normal cleavage of the cellular 
prion protein (Vincent et al. 2001). For ADAM-TS proteins, ADAM-TS2 can degrade 
procollagen (Tortorella et al. 1999, Tang 2001), and ADAM-TS1, 4, 5, and 9 have been 
shown to cleave the lectican family of chondroitin sulfate proteoglycans in vivo and/or in  
vitro , such as versicans, aggrecans, and brevican (Abbaszade et al. 1999, Tortorella et al. 
1999, 2000a, 2000b, Kuno et al. 2000, Sandy et al. 2000, Matthews et al. 2000, Sandy et al. 
2001, Sandy and Verscharen. 2001, Guo et al. 2002, Rodriguez-Manzaneque et al. 2002, 
Westling et al. 2002, Somerville et al., 2003). In addition, there are some peptide substrates 
available to determine the activities of ADAM9, 10, 17, 19 (Roghani et al. 1999, Kang et al. 
2002c), and ADAM9, 12, 15, 19 can form complex with alpha2-M and generate one or two 
products (Loechel et al. 1998, Lum et al. 1998, Roghani et al. 1999, Wei et al. 2001, Zhao et 
al. 2001, Kang et al. 2002b, 2002c).  
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     Another major function for ADAMs is able to mediate cell-cell interaction or cell-cell 
fusions by their disintegrin/cysteine-rich (DC) domains. Six different ADAMs, ADAM2, 9, 
12, 15, 23, 28 are able to interact with integrins such as alpha6beta1, alpha vbeta3, 
alpha9beta1, alpha vbeta5, alpha5beta1, and alpha4beta1, regulating cell-cell interactions in 
normal and pathological processes (Zhang et al. 1998, Nath et al. 1999, 2000, Eto et al. 2000, 
2002, Zhou et al. 2001, Evans 2001, Bridges et al. 2002, Seals and Courtneidge 2003). For 
example, human ADAM15, the only one containing the RGD sequence in ADAMs, is able to 
bind to alphavbeta3, alpha5beta1 and alpha9beta1 (Zhang et al. 1998, Nath et al. 1999, Evans 
2001). ADAM9 mediates cellular adhesion through alpha6beta1 or alphavbeta5 integrins 
(Nath et al. 2000, Zhou et al. 2001, Evans 2001). The binding of integrin alpha9beta1 to the 
ADAM12 and 15 disintegrin domains mediates cell-cell interaction (Eto et al. 2000, 2002, 
Evans 2001). The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the 
integrin alpha 4beta1 (Bridges et al. 2002). The disintegrin and cysteine -rich domains of 
ADAM13 bind to both fibronectin and beta1-containing integrin receptors, and this binding 
can be inhibited by antibodies against the cysteine-rich domain (Gaultier et al, 2002). 
Furthermore, the recombinant disintegrin/cysteine -rich domain of ADAM8 mediates cell 
adhesion in cells expressing ADAM8 (Schlomann et al. 2002). The disintergrin and cysteine-
rich domains of ADAM12 promotes the adhesion of fibroblasts and myoblasts (Zolkiewka, 
1999).  The disintegrin and cyste ine-rich domains of full length ADAM12 supports cell 
adhesion through syndecans and triggers signaling events that lead to beta1 integrin-
dependent cell spreading (Iba et al. 1999, 2000, Thodeti et al. 2003). Moreover, the 
disintegrin domains of ADAMs have been shown to mediate heterophilic and homophilic 
interactions, as in the cases of ADAM1, 2, 8. For instance, ADAM1 and ADAM2 can form 
heterodimers to mediate sperm-egg binding and fusion (Wolfsberg and White 1996). An 
alternatively spliced soluble ADAM12 interacts with IGFBP-3 through its cysteine-rich 
domain (Shi et al. 2000). The disintegrin and cysteine-rich domains of ADAM17 is required 
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for shedding of IL-1R-II while affecting the inhibitor sensitivity of TNF shedding (Reddy et 
al. 2000). Dr. DeSimone ’s group recently showed that the cysteine-rich domain of ADAM13 
cooperates intramolecularly with the metalloproteinase domain of ADAM13 to regulate its 
function in vivo (Smith et al., 2002) 
     It is noteworthy that ADAMs have been shown to play roles in multiple signal transduction 
pathways. In the case of the transactivation of epidermal growth factor receptor (EGFR)-
dependent signaling pathways upon stimulation of G-protein-coupled receptors (GPCRs), it is 
believed to be mediated by metalloproteinases, most likely by ADAMs, because the inhibition 
of proHB-EGF processing blocks GPCR-induced EGFR transactivation and downstream 
signals, and the treatment with the metalloproteinase inhibitor batimastat can inhibit the 
constitutive EGFR activity (Izumi et al. 1998, Prenzel et al, 1999, Nath et al. 2001, Yan et al. 
2002). The cytoplasmic domains containing SH3 binding sites in ADAMs may also be related 
to some signal pathways. For example, ADAM15 associates with a number of different 
proteins including adaptor s (endophilin I, SH3PX1, and Grb2), and three Src family tyrosine 
kinases (Src, Lck, and Hck) through its cytoplasmic domain (Howard et al. 1999, Poghosyan 
et al. 2002); ADAM9, like ADAM15, binds to endophilin I and SH3PX1 (Howard et al. 
1999).  ADAM12 cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is 
phosphorylated by v-Src at Tyr-901 (Suzuki et al. 2000). Furthermore, endogenous ADAM12 
associates with and activates endogenous Src in differentiating C2C12 cells by a direct and 
specific interaction between the SH3 binding sites in the cytoplasmic tail of ADAM12 and the 
SH3 domain of Src, and the direct interaction between the cytoplasmic tail of ADAM12 and 
the Src homology 3 domain of p85alpha activates phosphatidylinositol 3-kinase in C2C12 
cells (Kang Q et al. 2000, 2001). The cytoplasmic tail of ADAM12 can also ineract with 
alpha-actinin-2, a muscle-specific actin-binding and cross-linking protein (Galliano et al. 
2000, Cao et al. 2001). It was reported that PKC delta binds in vivo and in vitro  to the 
cytoplasmic domain of MDC9/meltrin-gamma/ADAM9, regulating the TPA-induced, 
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ADAM9-mediated shedding of HB-EGF (Izumi et al. 1998), and that MDC9 is 
phosphorylated in cells upon PMA treatment (Roghani et al. 1999). In addition, mitotic arrest  
deficient 2 (MAD2), which is a component of the spindle assembly (or mitotic) checkpoint 
mechanism, as a binding partner of the ADAM17 cytoplasmic domain, and a MAD2-related 
protein, MAD2beta, as a binding partner of the MDC9 cytoplasmic domain were identified 
(Nelson et al. 1999). SH3 binding sites of  ADAM19 cytoplasmic tail was shown to 
specifically interact with Arg, an oncoprotein, binding protein 1 (ArgBP1), beta-subunit of 
Coatomer protein (beta-cop), ubiquitin and another unknown protein by a yeast two-hybrid 
screening (Huang et al. 2002). 
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3. Results 
3.1 The Journal of Biological Chemistry, Vol. 277, No 28, Issue of July 12, 
2002, pp 25583-25591 
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Adamalysin 19 (a disintegrin and metalloproteinase 19,
ADAM19, or meltrin ) is a plasma membrane metallopro-
teinase. Human ADAM19 zymogen contains two potential
furin recognition sites (RX(K/R)R), 196KRPR200R and
199RRMK203R, between its pro- and catalytic domains.
Protein N-terminal sequencing revealed that the cellular
mature forms of hADAM19 started at 204EDLNSMK, dem-
onstrating that the preferred furin cleavage site was the
200RMK203R2204EDLN. Those mature forms were catalyt-
ically active. Both Pittsburgh mutant of 1-proteinase in-
hibitor and dec-Arg-Val-Lys-Arg-chloromethyl ketone,
two specific furin inhibitors, blocked the activation of
hADAM19. Activation of hADAM19 was also blocked by
brefeldin A, which inhibits protein trafficking from the
endoplasmic reticulum to the Golgi, or A23187, a calcium
ionophore known to inhibit the autoactivation of furin.
When 202KR were mutated to AA, the proenzyme was also
activated, suggesting that 197RPRR is an alternative acti-
vation site. Furthermore, only pro-forms of hADAM19
were detected in the 199RR to AA mutant, which abolished
both furin recognition sites. Moreover, the zymogens
were not converted into their active forms in two furin-
deficient mammalian cell lines; co-expression of
hADAM19 and furin in these two cell lines restored zymo-
gen activation. Finally, co-localization between furin and
hADAM19 was identified in the endoplasmic reticulum-
Golgi complex and/or the trans-Golgi network. This re-
port is the first thorough investigation of the intracellular
activation of adamalysin 19, demonstrating that furin ac-
tivated pro-hADAM19 in the secretory pathway via one of
the two consecutive furin recognition sites.
The adamalysin, ADAM1 (for a disintegrin and metallopro-
tease), or metalloprotease/disintegrin/cysteine-rich family in-
cludes proteins containing disintegrin- and metalloprotease-
like domains. These proteinases are involved in diverse
processes, such as development, cell-cell interaction, and pro-
tein ectodomain shedding (1–5). For example, ADAM10/kuzba-
nian (KUZ) and ADAM17/tumor necrosis factor- convertase
play key roles in the processing of both Notch1 receptor, which
is critical in development, and amyloid precursor protein,
which is related to the pathogenesis of Alzheimer’s disease (3,
4, 6). Six different ADAMs, ADAM2, -9, -12, -15, -23, and -28,
are able to interact with integrins such as 61, v3, 91,
v5, 51, and 41, regulating cell-cell interactions in normal
and pathological processes (7, 8). In the prodomain of ADAMs,
there is a cysteine switch sequence similar to the motif found in
matrix metalloproteases (MMPs) (9, 10), keeping ADAMs in
latent forms (2, 3, 11, 12). There are one or more furin cleavage
sites between the pro- and metalloprotease domains of almost
all members of the ADAM family discovered (2, 13–15), but
only several ADAM precursors, including ADAM1, -9, -12, -15,
and -17 and ADAMTS1, -4, and -12, have been shown to be
activated by furin or furin-like proprotein convertases (16–23).
Adamalysin 19/ADAM19, a type 1 membrane protein con-
taining an intact zinc-binding site in its metalloprotease do-
main, was cloned from mice (24, 25) and humans (26, 27).
Human adamalysin 19 was recently demonstrated to be an
active metalloproteinase through its cleavage of 2-macroglob-
ulin (2-M) in vitro (27). The endopeptidase activity of adama-
lysin 19 was blocked by specific antibodies against its catalytic
and disintegrin domain peptides (28). Mouse ADAM19 cleaved
intracellular neuregulin, a member of the epidermal growth
factor (EGF) family in vivo (29). Human ADAM19 and its
mouse homolog are highly similar, sharing 80.6% identity in
nucleotide sequences and 84.1% identity in amino acid se-
quences (24, 27). Among its many roles, hADAM19 may be
important in osteoblast differentiation (24), as a marker for the
differentiation and characterization of dendritic cells, in the
distinction between macrophages and dendritic cells (26), and
in the intracellular processing of neuregulin (29). ADAM19 is
synthesized as a zymogen, and its mechanism of activation has
not been thoroughly investigated.
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The proprotein convertases (PCs) are a large family of serine
proteinases that recognize dibasic or RX(K/R)R motifs and
cleave the peptide bond on the carboxyl side (30–32). As a
major proprotein convertase, furin is concentrated in the trans-
Golgi network (TGN) and cycles between this compartment and
the cell surface through the endocytic pathway. The autoacti-
vation and intracellular trafficking of furin are well character-
ized. Numerous studies have shown that furin activates a large
number of proproteins in multiple compartments (30–32). For
instance, furin has been demonstrated to mediate the activa-
tion of proenzymes, such as -amyloid-converting enzyme
(BACE), some matrix metalloproteinases (MMPs), including
MMP-11, -14, -16, and -24, and some ADAMs, including
ADAM1, -9, -12, -15, and -17 and ADAMTS1, -4, and -12 (16–
23, 30, 31, 33–40). However, the molecular mechanism and
pathway by which the cells regulate the potentially important
interactions between these proenzymes and the proprotein con-
vertase in cells are not fully understood. In this report, we
present evidence that furin is responsible for the activation of
hADAM19 and this activation can occur via one of the two
consecutive recognition sites and that furin is co-localized with
the substrate in the ER-Golgi complex and/or TGN.
EXPERIMENTAL PROCEDURES
Chemicals, Cell Lines, Cell Culture, and Immunological Reagents—
All common laboratory chemicals, proteinase inhibitors, brefeldin A
(BFA), anti-FLAG-M2 monoclonal antibody, and its agarose conjugates
were purchased from Sigma. Anti-furin antibodies were from Affinity
Bioreagents, Inc.(Golden, CO). Protein A/G PLUS agarose was from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The CMK-based furin
inhibitor dec-Arg-Val-Lys-Arg-chloromethyl ketone (decRVKR-CMK); a
calcium ionophore, A23187; and a matrix metalloproteinase inhibitor,
ilomastat (GM6001), were from BACHEM (Philadelphia, PA). Restric-
tion enzymes were from Promega or Invitrogen. COS1, Madin-Darby
canine kidney (MDCK), and derivative cells were maintained as de-
scribed (40–43). The furin-deficient Chinese hamster ovary-K1 strain
RPE.40 and furin-deficient COS-7 cell strain 7.P15 were cultured as
described (44). Dulbecco’s modified Eagle’s medium (DMEM), fetal bo-
vine serum (FBS), penicillin G, and streptomycin were from Invitrogen.
2-M was from Roche Molecular Biochemicals. Goat anti-mouse conju-
gated with fluorescein isothiocyanate and goat anti-rabbit-conjugated
rhodamine red were from Jackson Immunoresearch Laboratory, Inc.
(West Grove, PA). Rabbit polyclonal hADAM19 antibodies pAb361 (an-
ti-metalloproteinase domain) and pAb362 (anti-disintegrin domain)
were generated by our laboratory as reported (28).
PCR Primers, Mutagenesis, and Expression Constructs—pCR3.1uni-
ADAM19 wild type and mutants with or without the FLAG tag were
generated by high fidelity polymerase chain reaction with Pfu polym-
erase (Stratagene) as described (40–43). The primer sequences for wild
type ADAM19 were 5-ACC ATG CCA GGG GGC GCA GGC GCC-3
(forward primer) and 5-GAT TTT CGA GCT AAT CAT CCC TCC-3
(reverse primer). For deletion from the transmembrane domain to the
cytoplasmic domain, sequences were 5-ACC ATG CCA GGG GGC GCA
GGC GCC-3 (forward primer) and 5-AGG ACC CAC ACT CTC AGG
GGG-3 (reverse primer). For 196KR to AA mutant, sequences were
5-CAG ACC AAG GCG GCA CCT CGC AGG-3 (forward primer) and
5-CCT GCG AGG TGC CGC CTT GGT CTG-3 (reverse primer). For
199RR to AA mutant, sequences were 5-G AAG CGA CCT GCC GCG
ATG AAA AGG-3 (forward primer) and 5-CCT TTT CAT CGC GGC
AGG TCG CTT C-3 (reverse primer). For 202KR to AA mutant, se-
quences were 5-CGC AGG ATG GCA GCG GAA GAT TTA AAC-3
(forward primer) and 5-GTT TAA ATC TTC CGC TGC CAT CCT
GCG-3 (reverse primer). Expression constructs for the wild type full-
length form and the truncation form were named F46 and D52, respec-
tively. The 196KR to AA, 199RR to AA, and 202KR to AA mutants of
full-length and truncation forms were called 196RA-F, 196RA-D, 199RA-F,
199RA-D, 202RA-F, 202RA-D, respectively. All constructs were confirmed
by DNA sequencing. The expression vectors for furin and its soluble
form, paired basic amino acid-converting enzyme 4 (PACE4), 1-PI
(pAT), and Pittsburgh mutant of 1-PI (pATp) were constructed as
previously described (37).
DNA Transfection and Generation of Stable hADAM19 Expression
Cell Lines—LipofectAMINE 2000-mediated DNA transfections into
MDCK cells were performed following the instructions provided by
Invitrogen. Stable lines were selected in the presence of G418 (400
g/ml) and screened by Western blotting as described (40–42).
Western Blotting—The experiments were carried out as described
previously (40, 41). Briefly, cells were grown to 80% confluence and
were treated as indicated. After centrifugation at 14,000  g for 15 min
at 4 °C to clear any debris, the serum-free media were prepared for
SDS-PAGE. The cells were lysed with RIPA (50 mM Tris, pH 7.5, 150
mM NaCl, 0.25% sodium deoxycholate, 0.1% Nonidet P-40, 1 mM phen-
ylmethylsulfonyl fluoride, 2.5 M GM6001, 10 g/ml aprotinin, 10 g/ml
E64, and 10 g/ml pepstatin A) for 15 min in ice. The supernatant was
collected after centrifugation at 14,000  g for 20 min at 4 °C. After
electrophoresis, the proteins were transferred onto nitrocellulose mem-
branes and probed with anti-FLAG-M2 or anti-hADAM19 and devel-
oped as described (40, 41).
Purification of Soluble hADAM19 and Protein N-terminal Sequenc-
ing—All proteins were purified on anti-FLAG-M2 affinity columns as
described (42, 43). Briefly, cells stably expressing wild type soluble
hADAM19 (D52-5) or 199RR to AA mutant (199RA-D-6) were grown to
100% confluence, then washed with PBS twice and incubated for 48 h in
serum-free medium containing GM6001 (to prevent the degradation of
hADAM19). The conditioned media were collected, centrifuged to clear
debris, and loaded onto an anti-M2 immuno-affinity column (1 ml of
resuspended agarose) prewashed with Tris-buffered saline. The bound
materials were extensively washed with Tris-buffered saline, eluted
with FLAG peptides, and collected in 200-l fractions. The fractions
were analyzed by Western blot using anti-hADAM19 antibodies or
anti-FLAG-M2. The fraction containing the highest hADAM19 protein
concentration was prepared for protein N-terminal sequencing. After
separation by SDS-PAGE, the samples were transferred to a polyvinyli-
dene difluoride membrane and stained with Coomassie Blue R-250.
After destaining, the hADAM19 bands were excised and sent to the
Bioanalytical Core Facility at the Florida State University for N-termi-
nal amino acid sequencing.
2-M Trapping Assay to Determine Endopeptidase Activity of
hADAM19 Species—The detailed experimental procedure was previ-
ously reported (27, 28). Briefly, 10 l of the fraction containing purified
soluble hADAM19 was mixed with 24 l of 2-M (0.2 unit/ml), adjusted
to a total volume of 100 l by adding HEPES buffer (50 mM HEPES, pH
7.5, 200 mM NaCl, 10 mM CaCl2, 25 M ZnCl2, 0.05% Brij-35), and
incubated at 37 °C for 1–5 days. A 20-l aliquot of the mixture was
removed daily, put into 2 SDS-PAGE sample buffer, and boiled. Fol-
lowing SDS-PAGE, the protein bands in the gels were visualized by
silver staining.
Transient Transfection into COS1, RPE.40, or 7.P15 Cells—COS1,
RPE.40 or 7.P15 cells were seeded in 24- or 6-well plates for 16–24 h at
80% confluence prior to transfection. The cells were then transfected
with the indicated plasmids using LipofectAMINE 2000. After 6–10 h,
serum-free or 5% FBS DMEM containing 2.5 M GM6001, with or
without CMK, BFA, or A23187 at indicated concentrations, were added
for another 24 h. The conditioned media and cell lysates were analyzed
by Western blotting. For co-transfection experiments in these cells, the
indicated plasmid was transfected alone as a control and then co-
transfected with expression plasmids directing the production of furin,
PACE4, pAT, pATp, furin and pAT, or furin and pATp. After 6–10 h,
serum-free or 5% FBS DMEM containing GM6001 (2.5 M) was added
to the transfected cells for 16–24 h. Then, the conditioned media and
cell lysates were analyzed by Western blotting as described above.
Glycosylation Analysis—N-Glycosylation in vitro was investigated by
endoglycosidase F treatment as described previously (40, 41). Briefly,
transfected cells were grown to 80% confluence and incubated in serum-
free medium for 24 h. The conditioned media were then collected, and
the cells were lysed with RIPA. After centrifugation, the conditioned
media or the supernatant from RIPA were treated with glycosidase F (5
units, Roche Molecular Biochemicals) for 20 h at 37 °C and analyzed by
Western blotting.
Confocal Microscopy—The procedures have been described in detail
previously (38, 40). Briefly, MDCK cells expressing hADAM19 wild type
or 199RA mutant were grown on coverslips in six-well plates with or
without treatment with CMK, BFA, or A23187. After fixing with Lina’s
fixation buffer for 30 min, the cells were permeabilized with buffer A
(0.3% Triton X-100, 1% neutral detergent solution, 1% bovine serum
albumin, and 0.01% NaN3 in PBS) for 1 h and incubated for 3 h with
anti-furin and anti-FLAG-M2 (1:100 dilution in buffer A) for double
staining. After washing with PBS three times, secondary antibodies
conjugated with either fluorescein isothiocyanate or rhodamine red
were added to the cells for 1 h, followed by four washes with PBS.
Confocal microscopy experiments were performed at the Biological Sci-
ence Imaging Resource Facility at Florida State University.
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RESULTS
Removal of the hADAM19 Prodomain Is Dependent on Furin
Activity—The sequence of hADAM19 contains two potential
furin recognition sites (RX(K/R)R), 196KRPRRMK203R, be-
tween its pro- and catalytic domains (Fig. 1A). To ascertain the
role of furin in the cleaving of the hADAM19 prodomain, wild
type hADAM19 (F46) with a C-terminal FLAG tag was trans-
fected into COS1 cells alone or co-transfected with furin,
PACE4, 1-proteinase inhibitor (pAT), both furin and pAT,
Pittsburgh mutant of 1-proteinase inhibitor (pATp, a specific
inhibitor of furin) (37, 45), or both furin and pATp. As shown in
Fig. 1B, active hADAM19 forms were increased by the intro-
duction of furin, but not PACE4. Furthermore, pATp blocked
the processing of hADAM19; furin could not restore this proc-
essing when cells were co-transfected with furin and pATp
(lane 8). pAT had little effect on endogenous or furin-induced
processing of hADAM19 (lanes 2, 3, 5, and 6). Because pATp did
not completely block the hADAM19 processing, the low levels of
endogenous processing may also be meditated by other propro-
tein convertases in addition to furin (lanes 7 and 8).
Interestingly, both the pro- and active forms of hADAM19
were doublets. These doublets may be differentially glycosy-
lated forms. According to protein sequence analyses, hADAM19
has five potential glycosylation sites (27). Indeed, endoglycosi-
dase F converted the doublets into a single pro- or active form,
respectively (data not shown). To verify that the active
hADAM19 lacks a prodomain, hADAM19 antibodies against
the pro-, catalytic, or disintegrin domains (28) were used to
probe the proteins in the cell lysates. The results in Fig. 1C
clearly showed that the processed 80-kDa hADAM19 came
from the removal of its prodomain because it was not recog-
nized by the antibody against the prodomain peptide; however,
it was detected with antibodies against its catalytic and disin-
tegrin domains, respectively. These data showed that furin
activity played a major role for the intracellular removal of
hADAM19 prodomain.
To further demonstrate a direct role for furin in the activa-
tion of the hADAM19 zymogen, COS1 cells transfected with
wild type hADAM19 (F46) were incubated with dec-Arg-Val-
Lys-Arg-CMK (decRVKR-CMK), a widely used inhibitor of
furin (17, 38, 40, 46, 47). As shown in Fig. 2A, decRVKR-CMK
blocked the activation of hADAM19 in a dose-dependent man-
ner. Because furin is mainly localized in TGN and the autoac-
tivation of furin is calcium-dependent (48), we investigated
whether hADAM19 activation occurred in the trans-Golgi net-
work and required calcium. COS1 cells transfected with wild
type hADAM19 were treated with BFA, which blocks protein
trafficking from the ER to the Golgi apparatus (48, 49), or
A23187, a calcium ionophore known to inhibit the maturation
of furin (48). As shown in Fig. 2B, only the pro-forms of
hADAM19 were detected upon treatment with either BFA or
A23187. These results are consistent with furin-mediated ac-
tivation of hADAM19.
Deletion of the Transmembrane Domain and the Cytoplasmic
Tail of hADAM19 Does Not Alter the Processing of the Prodo-
main by Furin—To isolate soluble hADAM19 protein for en-
zyme activity assays, a construct encoding the extracellular
domain (ectodomain) of hADAM19 containing a C-terminal
FLAG tag was generated; this construct was called D52 and
lacked the transmembrane domain and cytoplasmic domain
FIG. 1. The prodomain removal of
hADAM19 by furin. A, a schematic dia-
gram of the hADAM19 domain structure.
The furin recognition sequence is shown
above the border between the pro- and cata-
lytic domains. SP, signal peptide; Pro-,
prodomain; Cat-, catalytic domain; Dis-, dis-
integrin domain; Cys-, cysteine-rich domain;
EGF-, EGF-like domain; TM, transmem-
brane domain; CD, cytoplasmic domain. B,
detection of hADAM19 by Western blotting
with anti-FLAG-M2 monoclonal antibody.
Cell lysates from COS1 cells transfected
with the blank vector (lane 1), pCR3.1-
hADAM19 (F46) alone (lane 2), or co-trans-
fected with plasmid encoding furin (lane 3),
PACE4 (lane 4), pAT (lane 5), pAT and furin
(lane 6), pATp (lane 7), or pATp and furin
(lane 8). The pro- and active forms of
hADAM19 are indicated. C, characteriza-
tion of hADAM19 using polyclonal antibod-
ies against different domains of hADAM19.
Cell lysates from lanes 1 and 2 in B were
analyzed by Western blotting with the fol-
lowing hADAM19 polyclonal antibodies: an-
ti-prodomain (Pro) (lanes 1 and 2), anti-cat-
alytic domain (Cat) (lanes 3 and 4), or anti-
disintegrin domain (Dis) (lanes 5 and 6).
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(Fig. 4A). This hADAM19 ectodomain construct was trans-
fected into COS1 cells. As shown in Fig. 3A, only the active
forms of soluble hADAM19 were detected in the media from
COS1 cells co-expressing the hADAM19 ectodomain and furin.
Both pro- and active forms were detected in the media from the
cells co-transfected with PACE4 or transfected with the ectodo-
main construct alone. Additionally, the active forms were de-
tected in the cell lysates only when cells were co-transfected
with furin (Fig. 3A, lanes 5–8).
A dose-dependent inhibition of soluble hADAM19 activation
by decRVKR-CMK was observed (Fig. 3B). However, there was
no significant effect of decRVKR-CMK on the intracellular
levels of hADAM19. Furthermore, there was no secretion of
soluble hADAM19 in the transfected cells treated with either
BFA or A23187 (Fig. 3C). Also, pATp dramatically decreased
the amount of active forms in the medium when it was ex-
pressed in COS1 cells, but pAT failed to do so (Fig. 3C). Once
again, no significant differences were seen in response to these
treatments in the cell lysates (Fig. 3C). These results show that
the soluble forms of hADAM19 were processed in the same
manner as the full-length form and are consistent with furin-
mediated activation of hADAM19.
There Are Two Alternative Furin Recognition Sites between the
Pro- and Catalytic Domain of hADAM19—Upon the examination
of the hADAM19 protein sequence, two consecutive furin recog-
nition sites (RX(K/R)R), 196KRPR200R and 199RRMK203R, were
found (Fig. 1A). We hypothesized that these two furin recognition
sites are alternatively used for the intracellular activation of
pro-ADAM19 by furin. To test this hypothesis, three mutants
were generated in full-length and ectodomain hADAM19, which
converted the 196KR, 199RR, and 202KR into AA, respectively.
These were named as 196RA-F, 196RA-D, 199RA-F, 199RA-D,
202RA-F, and 202RA-D, respectively, indicating that one (196RA-F,
196RA-D, 202RA-F, or 202RA-D) or no (199RA) furin recognition site
existed in the hADAM19 mutants (Fig. 4A).
All of the plasmids were transfected into COS1 cells to com-
pare the levels of activated hADAM19 for the wild type and RA
mutants in both the full-length (RA-F) and ectodomain forms
(RA-D). As shown in Fig. 4 (B and C), no active forms of 199RA
mutants were detected as a result of the absence of a furin
cleavage motif, whereas almost equivalent amounts of the ac-
tive forms of the 196RA and 202RA mutants were detected. The
wild type, full-length hADAM19 (Fig. 4B) and ectodomain form
(Fig. 4C) were studied in parallel with the mutants. In addi-
tion, the protein levels of hADAM19 were almost equal among
the cell lysates from these transfectants (Fig. 4, B and C).
These results strongly supported the hypothesis that process-
ing of the prodomain of hADAM19 was dependent on the pres-
ence of either one of the two consecutive furin recognition sites
between the pro- and catalytic domains.
To further confirm that furin processed hADAM19 via one of
the two alternative furin recognition sites, samples of the me-
dia from the four cell lines in Fig. 4C were incubated with the
medium containing soluble furin, which was obtained from the
FIG. 2. Blocking hADAM19 processing with CMK, BFA, or
A23187. A, dose-dependent inhibition of hADAM19 processing by de-
cRVKR-CMK. COS1 cells transfected with the blank vector (lane 1) or
pCR3.1hADAM19 (F46, lanes 2–5) were grown in 24-well plates with
0.1% methanol (v/v) (lanes 1 and 2) or CMK at 20 M (lane 3), 50 M
(lane 4), or 100 M (lane 5) for 24 h. The cell lysates were analyzed by
Western blotting with anti-FLAG-M2. B, prevention of the hADAM19
prodomain removal by BFA and A23187. COS1 cells were transfected
with the blank vector (lane 1) or F46 (lanes 2–4). Cells were grown in
24-well plates without (lanes 1 and 2) or with either 10 g/ml BFA (lane
3) or 0.5 M A23187 (lane 4) for 24 h. The cell lysates were analyzed as
in A.
FIG. 3. Activation of the ectodomain of hADAM19. A, enhance-
ment of the processing of soluble hADAM19 by furin. COS1 cells were
transfected with the blank vector (lanes 1 and 5), or vector expressing
soluble hADAM19 (D52) alone (lanes 2 and 6), or co-expressing with
furin (lanes 3 and 7), or with PACE4 (lanes 4 and 8). Both conditioned
media and cell lysates (lanes 5–8) were analyzed by Western blotting
with anti-FLAG-M2. B, dose-dependent inhibition of the processing of
soluble hADAM19 by CMK. The conditioned media (lanes 1–5) and cell
lysates (lanes 6–10) were from COS1 cells transfected with the blank
vector (lanes 1 and 6) or D52 (lanes 2–5 and 7–10). Cells were grown in
24-well plates with 0.1% methanol (v/v) (lanes 1, 2, 6, and 7) or CMK at
20 M (lanes 3 and 8), 50 M (lanes 4 and 9), and 100 M (lanes 5 and
10) for 12–16 h followed by incubation in serum-free media for 24 h.
Samples were analyzed by Western blotting as in A. C, processing of
soluble hADAM19 in the secretory pathway. COS1 cells were grown in
24-well plates overnight and then transfected with the blank vector
(lanes 1 and 7) or D52 alone (lanes 2–4 and 8–10), or co-transfected with
plasmids encoding either pAT (lanes 5 and 11) or pATp (lanes 6 and 12).
The next day, cells were treated with either 10 g/ml BFA (lanes 3 and
9) or 0.5 M A23187 (lanes 4 and 10) in serum-free medium for 24 h. The
conditioned media (lanes 1–6) or cell lysates (lanes 7–12) were analyzed
as in A.
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furin-transfected COS1 cell culture. The medium from COS1
cells transfected with a blank vector was used as a negative
control. As shown in Fig. 4D, soluble furin did not process the
199RA mutant of the soluble hADAM19. However, the wild type
and the mutant soluble proteins containing a furin recognition
motif were cleaved by furin. This furin-mediated processing
was sensitive to decRVKR-CMK inhibition, consistent with the
intracellular processing results obtained earlier (Figs. 3A and
4C). These results demonstrated that furin could activate
hADAM19 at both furin cleavage sites between the prodomain
and the catalytic domain of the zymogen.
Removal of the Prodomain Was Required for hADAM19 to
Exert Its Proteolytic Activity—In our previous reports, an in
vitro assay was established using 2-M to test the activity of
hADAM19 (27, 28). To assess the importance of zymogen acti-
vation to the proteolytic activity of hADAM19, stable lines of
wild type hADAM19 and its 199RA mutants were generated in
MDCK cells, in which the endogenous furin activity is high (38,
40, 50). One stable line was chosen from each group as a
representative to be treated with CMK, BFA, or A23187 and to
examine whether hADAM19 would display the same process-
ing as it did in COS1 cells. As predicted, CMK, BFA, or A23187
blocked the activation of wild type hADAM19 in the stably
transfected MDCK cells called F46-4 (Fig. 5A). MDCK cells
stably expressing the full-length 199RA (199RA-F-9) showed no
conversion of the pro-hADAM19 to its active form (Fig. 5A).
Furthermore, as shown in Fig. 5B, the active forms were only
detected in the medium from MDCK cells stably expressing
soluble hADAM19 (D52-5). When D52-5 cells were treated with
decRVKR-CMK for 24 h, the pro-forms of soluble hADAM19
were predominantly detected from the cell culture medium.
There were no active forms detected in the medium from the
199RA-D6 mutant cells, which were MDCK cells stably express-
ing soluble hADAM19 with the 199RA mutation (Fig. 5B).
Soluble hADAM19 proteins were purified from conditioned
media of D52-5 and 199RA-D6 cells. The endopeptidase activity
of the purified metalloproteinases was tested using an 2-M
trapping and cleaving assay. As shown in Fig. 5C, only the wild
type proteins could complex with 2-M and generate two
cleaved products. This activity was completely blocked by
EDTA. The 199RA mutant proteins were inactive, likely be-
cause the prodomain containing the cysteine switch residue
FIG. 4. Requirement of furin motifs between the pro- and catalytic domains for the activation of hADAM19. A, a schematic
illustration for the wild type expression vector pCR3.1hADAM19 and its mutant constructs. All the constructs have a C-terminal FLAG tag. SP,
signal peptide; Pro-, prodomain; Cat-, catalytic domain; Dis-, disintegrin domain; Cys-, cysteine-rich domain; EGF-, EGF-like domain; TM,
transmembrane domain; CD, cytoplasmic domain; F, FLAG tag. B, processing of hADAM19 in the 199RR to AA mutant is abolished. COS1 cells
were transfected with the blank vector (lane 1), F46 (lane 2), 196RA-F (lane 3), 199RA-F (lane 4), or 202RA-F (lane 5), and grown in 24-well plates
for 24–36 h. The cells were lysed with RIPA followed by SDS-PAGE and Western blotting with anti-FLAG-M2. C, inhibition of the processing of
the hADAM19 ectodomain in the 199RR to AA mutant. The conditioned media (lanes 1–5) and cell lysates (lanes 6–10) were from COS1 cells
transfected with the blank vector (lanes 1 and 6), D52 (lanes 2 and 7), 196RA-D (lanes 3 and 8), 199RA-D (lanes 4 and 9), or 202RA-D (lanes 5 and
10) overnight, followed by incubation in serum-free medium for 24 h. The samples were analyzed by Western blotting with anti-FLAG-M2. D,
activation of the soluble hADAM19 by exogenous soluble furin. The condition media from lanes 2–4 in C were mixed with equal volumes of
conditioned serum-free media from COS1 cells transfected with the blank vector (lanes 1, 4, 7, and 10) or soluble furin (lanes 2, 3, 5, 6, 8, 9, 11,
and 12). After being incubated with (lanes 3, 6, 9, and 12) or without 50 M CMK (lanes 1, 2, 4, 5, 7, 8, 10, and 11) at 37 °C for 24 h, the samples
were analyzed by Western blotting as in C.
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was not removed by furin (Fig. 5B). These results suggest that
hADAM19 activation also obeys the cysteine-switch mecha-
nism for zymogen latency and activation. Furthermore, N-
terminal sequences of the purified hADAM19 proteins from the
media revealed that the processed doublets (Fig. 5B, lane 2)
had the identical N-terminal sequences of 204EDLNSMK, sug-
gesting that furin prefers to cleave hADAM19 using the recog-
nition site of 200RMK203R rather than 197RPR200R. The dou-
blets have different glycosylation patterns as verified by
endoglycosidase F treatment experiments (data not shown).
These results confirmed the prediction that hADAM19 was
activated by furin through cleavage of the 203R-204E peptide
bond at the sequence 199RRMKR2204EDLNSMK.
Two Furin-deficient Cell Strains (RPE.40 and 7.P15) Do Not
Activate Pro-hADAM19, and the Introduction of Furin into
These Cells Restores Zymogen Activation—To further confirm
that furin activity was required for the intracellular activation
of pro-hADAM19, the wild type of full-length and soluble forms
of hADAM19 (F46 and D52) were transfected into RPE.40 cells
and 7.P15 cells, two furin-deficient cell strains (44, 51). Proc-
essing of hADAM19 to its mature forms was negligible in these
cell lines. However, the active forms were clearly detectable
when cells co-expressed furin (data not shown). As shown in
Fig. 6, there were barely detectable levels of the active forms of
soluble hADAM19 in the media of the two D52-transfected cell
lines. High levels of active forms were only detected in the
media when the cells co-expressed furin, although PACE4 also
increased the amount of active forms when it was co-expressed
with D52 (Fig. 6, A and B). Curiously, the active forms were
only detected in the lysates of cells co-expressing D52 and
furin. These data further confirm that furin was responsible for
the intracellular activation of hADAM19.
Furin Was Co-localized with hADAM19 in the ER-Golgi
Complex and/or TGN—To verify that hADAM19 was a phys-
iologically relevant substrate of furin, the cellular localization
of furin and hADAM19 was examined by confocal microscopy
using MDCK cells stably expressing hADAM19 (Fig. 7). Un-
treated cells are marked as F46-4 (control) (Fig. 7, top panels).
Co-localization of hADAM19 and furin was clearly observed,
and was consistent with ER-Golgi complex and/or TGN local-
izations (top, middle panel). Furthermore, hADAM19 was also
seen at the edges of the plasma membrane (right lane, top
panel) where furin was rare (left lane, top panel). Interestingly,
a similar pattern of co-localization between the 199RA mutant
and furin was also observed (Fig. 7, bottom panels), suggesting
that the co-localization was independent of the recognition
sites for furin in hADAM19. To test whether the agents that
block the activation of hADAM19 could prevent co-localization
between furin and hADAM19 (Fig. 5A), the cells were treated
with CMK, BFA, or A23187. None of these treatments inter-
fered with the co-localization pattern of furin and hADAM19
(Fig. 7), suggesting that furin may be co-localized with
FIG. 5. Requirement of the zymogen activation for the proteolytic activity of hADAM19. A, processing of hADAM19 in stably
transfected MDCK cells. MDCK cells stably expressing wild type hADAM19 (F46-4; lanes 2–5) or 199RA mutant (199RA-F-9; lane 6) were seeded
in six-well plates at 50% confluence. The next day, cells were treated with CMK (100 M, lane 3), BFA (10 g/ml, lane 4), or A23187 (0.5 M, lane
5). Lanes 2 and 6 represent untreated controls. The cells were lysed with RIPA followed by analysis of Western blotting using anti-FLAG-M2.
MDCK cells stably transfected with the blank vector were an additional control (lane 1). B, the requirement of furin in the processing of soluble
hADAM19 in stably transfected MDCK cells. MDCK cells stably expressing soluble hADAM19 (D52-5) (lanes 2, 3, 6, and 7) or soluble 199RA mutant
(199RA-D-6) (lanes 4 and 8) were grown in 24-well plates to 100% confluence. Cells were incubated in serum-free media without (lanes 1, 2, 4, 5,
6, and 8) or with CMK (100 M, lanes 3 and 7) for 24 h. Both conditioned media (lanes 1–4) and lysates (lanes 5–8) were analyzed by Western
blotting as in A. MDCK cells stably transfected with the blank vector is a control (lane 1). C, the proteolytic activity of soluble mature hADAM19.
Purified soluble hADAM19 from D52-5 and 199RA-D6 were incubated in reaction buffer alone (lanes 1 and 2) or with 2-M in the absence (lanes
4 and 5) or presence of EDTA (lane 5) for 48 h. 2-M in reaction buffer alone (48 h) was a control (lane 3). The 2-MhADAM19 complex and the
cleavage products of 2-M by hADAM19 are labeled on the right. Note that pro-soluble hADAM19 (
199RA-D-6) did not form the complex with 2-M.
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hADAM19 in perinuclear ER-Golgi complex and/or TGN inde-
pendent of the furin catalytic activity.
DISCUSSION
Proteolysis of the extracellular matrix and cell surface pro-
teins mediated by metalloproteases, including MMPs and
ADAMs, is of vital importance for tissue-remodeling processes
during normal and pathological conditions, such as tissue mor-
phogenesis, wound healing, inflammation, and tumor cell in-
vasion and metastasis (3–7, 52, 53). Metalloproteases are syn-
thesized as inactive proenzymes or zymogens, and their latency
is maintained by a cysteine-switch residue in the propeptide
domain in which the thiol group is coordinated to the active site
zinc (II) (2, 9–12). To display any proteolytic activities, the
prodomain located N-terminal to the catalytic domain must be
removed from the zymogen in most cases. Recently, PCs, such
as furin and or furin-like serine peptidases, have been recog-
nized as very important enzymes for the zymogen activation,
although various mechanisms have been proposed for the acti-
vation of pro-MMPs and pro-ADAMs. Furin or furin-like PCs
mediate zymogen activation by recognizing a conserved RX(K/
R)R motif in the boundary between pro- and catalytic domains.
This motif is present in almost all ADAMs and nine MMPs (2,
13, 53). By analyzing the intracellular activation of hADAM19,
we have demonstrated that both furin activity and one of the
two consecutive sites in 197RPRRMK203R in ADAM19 are re-
quired for activation, which is dependent on calcium and
proper secretory pathway trafficking. Furthermore, we have
provided direct evidence that furin is co-localized with
hADAM19 in ER-Golgi complex and/or TGN. This colocaliza-
tion between furin and hADAM19 is independent of the furin
recognition site and is resistant to a variety of treatments, such
as CMK, BFA, and A23187, that inhibit furin activity, vesicular
trafficking, and calcium signal, respectively. These findings are
consistent with the report published recently showing that
furin was co-localized with MMP16 independent of their appar-
ent enzyme-substrate relationship (40).
Latency and Activation of ADAMs—The classic cysteine
switch mechanism for pro-MMP latency and activation was
originally proposed for MMPs (10) and may be applied for many
MMPs discovered with the exception of MMP-3, MMP-23, and
MMP-26 (41, 54–58). The activation of pro-MMP-3 by a mer-
curial compound was triggered by a perturbation of the confor-
mation of the precursor rather than a direct disruption of the
Cys-zinc interaction (54). A salt bridge in pro-MMP-3 might
also contribute to the latency of the proenzyme (55). Organo-
mercurial treatment failed to activate pro-MMP-26 with a
unique cysteine-switch motif, PH81CGXXD, and when the con-
served cysteine-switch sequence, PR81CGXXD, in the prodo-
main of pro-MMP-26 was restored by mutagenesis, the cys-
teine-switch activation mechanism was not induced (58).
Regarding the ADAM family members, the active ADAMs,
such as ADAM1, -9, -10, -12, -15, -17, -19, -28, and ADAMTS1,
-4, and -12, contain a catalytic site consensus sequence
(HEXXH) in their metalloprotease domains (2, 11–14, 16–21,
27–29, 53, 59–61). They may also have a putative cysteine-
switch residue in their prodomain to keep them inactive (9).
For example, the investigation by Leochel et al. (11) demon-
strated that the latency and activation mechanism of ADAM12
was similar to the cysteine switch model proposed for MMPs.
ADAM9, -15, and -17 showed catalytic activity against their
substrates only after their prodomains were removed (12, 21,
22). However, for many ADAMs, including ADAM19, no direct
evidence has been provided to support the hypothesis that the
Cys-zinc coordination is required for latency. For ADAM17/
tumor necrosis factor- convertase, the prodomain was not only
an inhibitor of the catalytic domain, but also appeared to act
like a chaperone, facilitating secretion, folding, or both of the
ADAM protein (12). In this report, we have demonstrated that,
after the removal of the prodomain of hADAM19 by furin, the
enzyme has endopeptidase activity against 2-M. However,
furin is unable to cleave the prodomain of the 199RR to AA
hADAM19 mutant lacking a furin recognition site in the
boundary of the pro- and catalytic domains. This mutant has no
FIG. 6. Processing the hADAM19 prodomain in furin-deficient
mammalian cell lines. A, hADAM19 in 7.P15 cells. 7.P15 cells were
transfected with the blank vector (lanes 1 and 5) or D52 alone (lanes 2
and 6) or co-transfected with D52 and plasmids encoding furin (lanes 3
and 7) or PACE4 (lanes 4 and 8). Cells were grown in 24-well plates for
12–16 h followed by incubation in serum-free medium for 24 h. Condi-
tioned media (lanes 1–4) and cell lysates (lanes 5–8) were analyzed by
Western blotting with anti-FLAG-M2. B, hADAM19 in RPE.40 cells.
RPE.40 cells were transfected with the blank vector (lanes 1 and 5) or
D52 alone (lanes 2 and 6) or were co-transfected either D52 and plas-
mids encoding furin (lanes 3 and 7) or PACE4 (lanes 4 and 8). Cells were
grown in 24-well plates overnight followed by incubation in serum-free
media for 24 h. Conditioned media (lanes 1–4) and cell lysates (lanes
5–8) were analyzed by Western blotting as in A.
FIG. 7. Co-localization of hADAM19 and furin. MDCK cells sta-
bly expressing wild type hADAM19 (F46-4) or 199RA mutant (199RA-
F-9) grown on coverslips in six-well plates were treated with nothing
(control), 100 M CMK, 10 g/ml BFA, or 0.5 M A23187 for 24 h. The
fixed slides were stained for both hADAM19 with anti-FLAG-M2 (right
panels) and furin with anti-furin (left panels). The merged pictures for
both hADAM19 and furin are presented in the middle column. Note
that hADAM19 is co-localized with furin, independent on furin motif,
with neither CMK, BFA, nor A23187 altering the staining pattern.
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proteolytic activity using an 2-M trapping assay. These results
demonstrate that at least one of the furin recognition sites is
required for the removal of the propeptide domain by furin to
activate pro-hADAM19. The detailed mechanism of pro-
ADAM19 latency and activation and the role of the cysteine-
switch sequence remain to be further investigated.
For the activation of ADAM zymogens, two mechanisms have
been reported. One is the removal of the prodomain by autol-
ysis, but it was shown only in ADAM28 (60). The predominant
mechanism for the activation of ADAMs is mediated by furin or
furin-like PCs in the secretory pathway. This mechanism has
been shown in many ADAMs, including ADAM1, -9, -12, -15,
-17, and -19, and ADAMTS1, -4, and -12, using N-terminal
sequencing, specific inhibitors of furin, blockers of protein traf-
ficking from ER to Golgi, exogenous soluble furin in vitro,
furin-deficient cell lines, and mutagenesis at the furin recogni-
tion site(s) (RX(K/R)R) between the pro- and catalytic domain
(Refs. 16–23; this report). In the present report, we provide a
thorough investigation of ADAM zymogen activation mediated
by furin (Figs. 1–6) and evidence that furin is co-localized with
ADAMs in the ER-Golgi complex and/or TGN (Fig. 7), showing
that ADAMs are similar to MMPs in these respects (38, 40).
There Are Two Consecutive Furin Recognition Sites in the
Boundary of the Pro- and Catalytic Domains of hADAM19—
The minimal furin recognition sequence requires basic residues
at P1 and P4 (RXXR) and in some cases, at the P1 position, an
amino acid with a hydrophobic aliphatic side chain is not suit-
able (31). Typically, there is only one furin recognition site
between the pro- and catalytic domain of the substrates of furin
as found in most members of the ADAM family, seven MMPs,
pro-BACE, and Notch1 receptor (2, 13–15, 30, 31, 33–40, 53,
62). In this report, we present evidence for the first time that
there are two consecutive furin recognition sites, 197RPR200R
and 200RMK203R, between the pro- and catalytic domain in
hADAM19, which adhere to the rules for efficient cleavage by
furin (31). Only pro-forms were detectable in the 199RA mutant,
which lacked a furin recognition site between its pro- and
catalytic domain, whereas the mutants of both 196RA and
202RA, which possessed recognition sites, were converted into
the active forms. Thus, the Arg residue at the P4 site is required
for the intracellular hADAM19 maturation mediated by furin
(Figs. 4 and 5B). Interestingly, N-terminal sequencing of wild
type mature forms (Fig. 5) confirmed that the preferred intra-
cellular cleavage site for hADAM19 activation is the one nearer
to the catalytic domain, 200RMK203R, as predicted before (26,
27). This motif is conserved in mice as 201RMK204R (24). The
distal motif, 197RPR200R in humans, however, is replaced with
198QPR201R in mice, which is not efficiently cleaved by furin.
A notion that pro-hADAM19 activation by furin may be
sequential, i.e. 200R201M is cleaved first followed by 203R204E,
seems to be consistent with the partially activated soluble
species seen for 196RA-D compared with 202RA-D data in Fig.
4C; however, it does not agree with the data shown in Fig. 4B,
where it is seen that the presence of furin with the full-length
196RA-F leads to more activated species than 202RA-F. The
delicate changes in the interactions between furin and the
different mutants that have subtle structural and conforma-
tional differences might be partially responsible for the differ-
ent activation levels observed. Moreover, among all the protein
N-terminal sequence data of wild type hADAM19 activated
species, only 204EDLNSMK was found; the alternative cleavage
site product of 201MKRED was not detected. Most importantly,
the minimal furin recognition sequence requires basic residues
at P1 and P4 (RXXR) and the Arg residue at the P4 site is
required for the intracellular hADAM19 maturation mediated
by furin (Figs. 4 and 5B). It may not be possible for furin, an
endopeptidase, to effectively cleave the product of the 200R-
201M cleavage because the 201MK203R-204ED sequence lacks
the required Arg at the P4 site. Thus, our data suggest that the
203R-204E site is the predominant cleavage site and 200R-201M is
an alternative cleavage site by furin when the predominant site
is missing. This is consistent with the model proposed for wild
type MT1-MMP, in which the pro-MT1-MMP is processed pri-
marily at the 108RRKR site to generate the active proteinase
and the secondary site within 86KXXRRXR is cleaved only
when the primary 108RRKR motif was mutated (39).
Notably, there are two potential consecutive furin recogni-
tion sites in other metalloproteinase zymogens, including
ADAM11 (AB009675, 292RLRRK297R), ADAM22 (AF155382,
219RPKRSK225R), ADAMTS4 (AF148213, 206RPRRAK212R),
MT2-MMP (NM_002428, 126RRRRK131R), and MT5-MMP
(AJ010262, 118RRRRNK224R). The ones nearer to the catalytic
domains are conserved in different species, whereas the distal
ones might be acquired later during evolution. Although the
significance of the two alternative recognition sites in these
precursors remains poorly understood, we may speculate that
the processing of these zymogens are crucial for some biological
events; the zymogens may be activated by furin at a different
cleavage site even if the primary site is abolished by mutation.
Significance of Furin and Its Related PC Pathways in the
Processing of Precursors—Furin and its related PCs have been
demonstrated as the major enzymes responsible for the matu-
ration of many precursors, such as some ADAMs and MMPs
(Refs. 16–23 and 37–40; this report). Furthermore, zymogens
of BACE, a major enzyme related to Alzheimer’s disease, and
some growth factors and cell surface receptors, such as trans-
forming growth factor , insulin-like growth factor, hepatocyte
growth factor receptor, and Notch1 receptor, are converted into
their active forms by these PC pathways (30, 31, 33–36, 62).
Thus, this activation mechanism by a PC may play key roles in
many physiological and pathological events. In fact, furin
knockout mice are embryonic lethal (63), and inhibition of furin
results in absent or decreased invasion and tumorigenicity of
human cancer cells (64, 65). The inability to activate many
types of proproteins, including some pro-ADAMs and pro-
MMPs, in furin null mice may contribute to the abnormal
phenotypes during early development and morphogenesis in
those mice. On the other hand, the design and synthesis of
furin specific inhibitors may lead to a new strategy in the
treatment of cancer and other diseases, such as Alzheimer’s
disease, in the human adult.
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We investigated the regulation of the proteolytic
activity of human adamalysin 19 (a disintegrin and
metalloproteinase 19, hADAM19). It was processed at
Glu586(P1)-Ser587(P1) site in the cysteine-rich domain as
shown by protein N-terminal sequencing. This trunca-
tion was autolytic as illustrated by its R199A/R200A or
E346A mutation that prevented the zymogen activation
by furin or abolished the catalytic activity. Reagents
that block furin-mediated activation of pro-hADAM19,
decRVKR-CMK, A23187, and brefeldin A abrogated this
processing. The sizes of the side chains of the P1 and P1
residues are critical for the processing of hADAM19. The
amount of processing product in the E586Q or S587A
mutant with a side chain almost the same size as that in
the wild type was almost equal. Conversely, very little
processing was observed when the size of the side chain
was changed significantly, such as in the E586A, E586G,
or S587F mutants. Two mutants with presumably subtle
structural distinctions from wild type hADAM19, E586D
and S587T, displayed rare or little processing and had
very low capacities to cleave 2-macroglobulin and a
peptide substrate. Therefore, this processing is neces-
sary for hADAM19 to exert its proteolytic activities.
Moreover, a new peptide substrate, Ac-RPLE-SNAV,
which is identical to the processing site sequence, was
cleaved at the E-S bond by soluble hADAM19 containing
the catalytic and disintegrin domains. This enzyme
cleaved the substrate with Km, kcat, and kcat/Km of 2.0
mM, 2.4/min, and 1200 M1 min1, respectively, using a
fluorescamine assay. Preliminary studies showed that a
protein kinase C activator, phorbol 12-myristate 13-
acetate, promoted the cellular processing of hADAM19;
however, three calmodulin antagonists, trifluoperazine,
W7, and calmidazolium, impaired this cleavage, indicat-
ing complex signal pathways may be involved in the
processing.
Ectodomain shedding is a process in which a wide variety of
transmembrane proteins, such as growth factors and growth
factor receptors, cytokines and their receptors, amyloid precur-
sor protein (APP),1 adhesion molecules, and enzymes, proteo-
lytically release their extracellular domains. It is believed to
play key roles in normal development, arthritis, inflammation,
and tumorigenesis (1–5). Although the signal pathways regu-
lating ectodomain shedding remain poorly understood, numer-
ous studies have shown that structurally different proteins
share common pathways (5–8). For example, phorbol 12 my-
ristate 13-acetate (PMA), a protein kinase C (PKC) activator, is
generally a potent inducer of ectodomain shedding. Other sig-
nals, such as calcium, calmodulin (CaM), tyrosine kinase, mi-
togen-activated protein kinase (MAPK), and phosphatase, also
play roles in certain shedding processes (9–23). On the other
hand, the shedding process, in most cases, is hindered by hy-
droxamate-based inhibitors of metalloproteinases, such as
BB94, GM6001, and tumor necrosis factor- proteinase inhib-
itor (TAPI) (5–8, 19, 24–26).
Inhibitor studies have shown that TIMP-3, not TIMP-1 or
TIMP-2, impairs many shedding processes, indicating that the
proteins comprising the a disintegrin and metalloprotease
(ADAM)/adamalysin/metalloprotease, disintegrin, cysteine-
rich (MDC) family, rather than the matrix metalloproteinase
(MMP) family, are the predominant sheddases (27–30). Indeed,
five ADAMs have been implicated in shedding processes so far.
ADAM17/TACE, a major sheddase, has a role in the shedding
of tumor necrosis factor- (TNF-), transforming growth fac-
tor- (TGF-), L-selectin, both TNF receptors, interleukin-1
receptor II, HER4, Notch, and TNF-related activation-induced
cytokine (TRANCE). It also acts as a PMA-induced APP
-secretase (1–6, 31). ADAM10/Kuzbanian, another major
sheddase, is required for Notch signaling. It can cleave the
Notch ligand Delta, heparin-binding epidermal growth factor
(HB-EGF), TNF-, L1 adhesion molecule, and ephrin A2 and is
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an APP -secretase (1–5, 32, 33). ADAM9 is believed to partic-
ipate in the PMA-stimulated shedding of HB-EGF (34) and can
function as an APP -secretase (35). ADAM19/MDC  has been
linked to shedding of the epidermal growth factor receptor-
ligand neuregulin-1 (36). ADAM12/MDC  has recently been
shown to be responsible for endogenous shedding of HB-EGF in
the heart (37). In addition, MMP7 has a functionally relevant
role in shedding of TNF- and FasL (38, 39), and MT1-MMP
can be autolytically shed and is an enzyme capable of releasing
both CD44 and TRANCE (21, 40, 41). However, not many
proteinases responsible for ectodomain shedding of proteins
have been identified.
Adamalysin 19/ADAM19/MDC , cloned from mice (42, 43)
and humans (44, 45), is a type I membrane-bound protein
containing the basic domains of ADAMs, such as the prodo-
main, metalloprotease and disintegrin domain, cysteine-rich
domain, transmembrane domain, and cytoplasmic domain (3).
In addition to the processing of neuregulin (NRG) (36), human
adamalysin 19 (hADAM19) is believed to play a role in osteo-
blast differentiation, in the distinction between macrophages
and dendritic cells, and as a marker for the differentiation and
characterization of dendritic cells (44). Recently, we demon-
strated that hADAM19 is activated by furin in the secretory
pathway and that the intracellular removal of the prodomain is
required for its proteolytic activity, which was assessed with an
2-macroglobulin (2-M) trapping assay in vitro (46). Emerg-
ing evidence indicates that metalloproteinase activity is regu-
lated by the process of shedding or truncation, as in the cases
of MT1-MMP, MT5-MMP, ADAM13, and ADAMTS4 (40, 47–
49). Here we show that autolytic processing at Glu5862 Ser587
of hADAM19 within its cysteine-rich domain is required for its
endopeptidase activity and that efficient processing of
hADAM19 is mainly dependent on the sizes of both Glu586 and
Ser587. We also show that PKC, CaM, and calcium signals may
regulate the hADAM19 processing, which is not sensitive to
GM6001 or TIMP-3. Moreover, we present a peptide substrate
that mimics the processing site and may be used to determine
the activity of soluble hADAM19 by a fluorescamine assay.
MATERIALS AND METHODS
Chemicals, Cell Lines, Cell Culture, and Immunological Reagents—
All common laboratory chemicals, proteinase inhibitors, PMA, triflu-
operazine, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W7),
calmidazolium, PD98059, wortmannin, LY290042, pervanadate, and
anti-FLAG-M2 monoclonal antibody (mAb) and its agarose conjugates
were purchased from Sigma Chemical Co. (St. Louis, MO). The CMK-
based furin inhibitor, dec-Arg-Val-Lys-Arg-chloromethyl ketone (de-
cRVKR-CMK), and a matrix metalloproteinase inhibitor, ilomastat
(GM6001), were purchased from Bachem (Philadelphia, PA). TIMP-3
was purchased from R & D Systems (Minneapolis, MN). Restriction
enzymes were purchased from Promega (Madison, WI) or Invitrogen
(Gaithersburg, MD). COS1 and Madin-Darby canine kidney (MDCK)
cells and its derivatives were maintained as described (45). Dulbecco’s
modified Eagle’s medium was purchased from Invitrogen (Gaithers-
burg, MD). Fetal bovine serum, penicillin G, and streptomycin were
purchased from Invitrogen (Rockville, MD). 2-M was purchased from
Roche Molecular Biochemicals (Indianapolis, IN). Rabbit polyclonal
hADAM19 antibodies pAb361 (anti-metalloproteinase domain, anti-
Cat) and pAb362 (anti-disintegrin domain, anti-Dis) were generated by
our laboratory as reported previously (50).
PCR Primers, Mutagenesis, and Expression Constructs—All inserts
tagged with FLAG at their C terminus were cloned into pCR3.1uni,
including wild type hADAM19 (F46), soluble hADAM19 (D52), 199RA-D
(described in Ref. 46), and all mutants used in this study. The primer
sequences for full-length (E346A-F) and soluble (E346A-D) Glu346 3
Ala mutants were: forward primer, 5-C ATG GCC CAC GCG ATG
GGC CAC-3; reverse primer, 5-GTG GCC CAT CGC GTG GGC CAT
G-3. For deletion from the cysteine-rich domain to the end of the C
terminus (D-CR): forward primer, 5-ACC ATG CCA GGG GGC GCA
GGC GCC-3; reverse primer, 5-GGT ACC ATC CAT CTG GTA GAA
G-3. For the soluble Glu5863 Ala mutant (E586A-D): forward primer,
5-CGG CCC CTG GCG TCC AAC GCG-3; reverse primer, 5-CGC
GTT GGA CGC CAG GGG CCG-3. For the soluble Glu586 3 Gly
mutant (E586G-D): forward primer, 5-CGG CCC CTG GGG TCC AAC
GCG-3; reverse primer, 5-CGC GTT GGA CCC CAG GGG CCG-3.
For the soluble Glu586 3 Asp mutant (E586D-D): forward primer,
5-CGG CCC CTG GAC TCC AAC GCG-3; reverse primer, 5-CGC
GTT GGA GTC CAG GGG CCG-3. For the soluble Glu586 3 Gln
mutant (E586Q-D): forward primer, 5-CGG CCC CTG CAG TCC AAC
GCG-3; reverse primer, 5-CGC GTT GGA CTG CAG GGG CCG-3.
For the soluble Ser587 3 Ala mutant (S587A-D): forward primer, 5-
CCC CTG GAG GCC AAC GCG GTG-3; reverse primer, 5-CAC CGC
GTT GGC CTC CAG GGG-3. For the soluble Ser587 3 Thr mutant
(S587T-D): forward primer, 5-CCC CTG GAG ACC AAC GCG GTG-3;
reverse primer, 5-CAC CGC GTT GGT CTC CAG GGG-3. For the
soluble Ser587 3 Phe mutant (S587F-D): forward primer, 5-CCC CTG
GAG TTC AAC GCG GTG-3; reverse primer, 5-CAC CGC GTT GAA
CTC CAG GGG-3. All constructs were confirmed by DNA sequencing.
DNA Transfection and Generation of Stable Cell Lines—COS1 cells
were seeded into 24-well plates for 16–24 h at 80% confluence and
transfected with the indicated plasmids using LipofectAMINE2000 ac-
cording to the instructions provided by Invitrogen (Gaithersburg, MD).
After 6–10 h, serum-free Dulbecco’s modified Eagle’s medium and the
indicated reagents were added, and the mixture was incubated for
another 24 h. The conditioned media and cell lysates were then ana-
lyzed by Western blotting (46). The same transfection procedure was
performed to generate stable MDCK cell lines, and the selection for
hADAM19 was begun in the presence of G418 (400 g/ml) after trans-
fection for 24 h. The conditioned media and/or cell lysates of the clones
were subjected to Western blotting to confirm the expression of
hADAM19 (46).
Western Blotting—The experiments were carried out as described
previously (46). Briefly, cells were grown to 80% confluence and were
treated as indicated. After centrifugation for 15 min at 14,000  g and
4 °C to clear any debris, the serum-free media were collected and
prepared for SDS-PAGE. The cells were lysed with RIPA buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 0.25% sodium deoxycholate, 0.1% Nonidet
P-40, 1 mM phenylmethylsulfonyl fluoride, 2.5 M GM6001, 10 g/ml
aprotinin, 10 g/ml E64, and 10 g/ml pepstatin A) for 15 min on ice.
The supernatant was collected after centrifugation for 20 min at
14,000  g and 4 °C. After electrophoresis, the proteins were trans-
ferred onto nitrocellulose membranes, probed with anti-FLAG-M2 or
anti-hADAM19, and developed as before (46).
Purification of Soluble hADAM19 and N-terminal Sequencing—All
proteins were purified on anti-FLAG-M2 affinity columns as described
previously (46); however, HEPES buffer (50 mM HEPES, pH 7.5, 200
mM NaCl, 10 mM CaCl2, 25 M ZnCl2, 0.05% Brij-35) was used instead
of TBS buffer for the purpose of determining the activity of hADAM19
by a fluorescamine assay. Briefly, cells from stable lines expressing
soluble hADAM19, D52-5, E586D-D, S587T-D, and D-CR, were grown to
100% confluence, washed twice with phosphate-buffered saline, and
incubated for 48 h. in serum-free media. The conditioned media were
collected, centrifuged to clear any debris, and loaded onto an anti-M2
immunoaffinity column (1 ml of resuspended agarose) that had been
prewashed with HEPES buffer. The bound materials were extensively
washed with HEPES buffer, eluted with FLAG peptides, and collected
in 500-l fractions. The fractions were analyzed by Western blot using
anti-hADAM19 antibodies or anti-FLAG-M2, and the protein was quan-
tified by its UV absorbance at 280 nm. The fractions containing the
most wild type or mutant hADAM19 proteins were used for the 2-M
trapping assay and fluorescamine assay. In the case of D52-5, the most
concentrated fraction was also prepared for protein N-terminal se-
quencing to determine the shedding site. After separation by SDS-
PAGE, the samples were transferred to a PVDF membrane and stained
with Coomassie Blue R-250. After destaining, the hADAM19 bands
were excised and sent to Margaret Seavy at the Bioanalytical Core
Facility at the Florida State University for N-terminal amino acid
sequencing.
2-M Trapping Assay—The detailed experimental procedure was
previously reported (46, 50). Briefly, equal amounts of purified wild
type and mutated soluble hADAM19 were mixed with 24 l of 2-M (0.2
unit/ml), respectively, adjusted to a total volume of 100 l with HEPES
buffer, and incubated at 37 °C for the indicated times. A 20-l aliquot of
the mixture was removed at the indicated times, put in 2 SDS-PAGE
sample buffer, and boiled. Following SDS-PAGE, the protein bands in
the gels were visualized by silver staining.
Determination of Kinetic Parameters of hADAM19 Using a New Pep-
tide Assay—The N-terminal acetylated peptide (Ac-RPLESNAV) was
synthesized by Dr. Umesh Goli at the Biochemical Analysis, Synthesis,
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and Sequence Service Laboratory at Florida State University. The stock
solutions of the peptide substrates were prepared in 0.05 M HEPES, pH
7.5, 0.2 M NaCl, 0.01 M CaCl2, and 0.01% Brij-35. The peptide concen-
trations ranged from 0.2 to 4.0 mM, and the enzyme concentration was
160 nM. N-terminal sequencing for this released peptide was performed
after overnight hydrolysis by the enzyme. Hydrolysis of the peptide by
the enzyme was monitored by measuring fluorescence intensity (51).
After incubation for the indicated times, the hydrolytic reaction was
quenched by adding 20 l of 100 mM 1,10-phenanthroline into 100 l of
reaction mixture. For the control sets, the 1,10-phenanthroline solution
was added at the start of incubation. After the reaction was quenched,
100 l of 0.1% fluorescamine in 10% Me2SO/90% assay buffer was
added into each reaction mixture. Relative fluorescence of the product
coupled with fluorescamine was determined on a PerkinElmer Life
Sciences LS-50B spectrofluorometer using an excitation wavelength of
386 nm and an emission wavelength of 477 nm. Excitation and emission
slit widths were both 10 nm. Relative fluorescence was converted to
nanomoles of product using a standard curve obtained with arginine.
The final solution was diluted further with the assay buffer, if it was
necessary. The values of kcat and Km were determined by fitting the data
to the Michaelis-Menten equation. A molar extinction coefficient of
33,120 M1 cm1, which was calculated by using Genetic Computer
Group (GCG) software, was used to determine the concentration of
soluble hADAM19.
RESULTS
hADAM19 Is Processed within the Cysteine-rich Domain—
Shedding or truncation is increasingly being recognized as a
key regulator of the activity of some metalloproteinases (40,
47–49). It was intriguing to investigate the possibility of shed-
ding or truncation in hADAM19. As shown in Fig. 1A, in addi-
tion to the pro and active forms of hADAM19, we detected a
doublet of protein of about 58 kDa by anti-FLAG-M2 in the
lysate of the transfected COS1 cells expressing full-length
hADAM19 with C-terminal FLAG tags (F46). We did not detect
the doublet using antibodies against the catalytic and disinte-
grin domains of hADAM19, indicating that the 58-kDa protein
is the processed C-terminal fragment lacking the metallopro-
teinase and disintegrin domains of hADAM19. On the other
hand, another doublet of around 72 kDa was detected in the
same lysate by these two hADAM19 antibodies but not anti-
FLAG-M2 (Fig. 1A), suggesting that the 72-kDa protein is the
processed N-terminal fragment containing the metalloprotein-
ase and disintegrin domains of hADAM19. Taken together, a
cellular processing occurs in hADAM19 after its disintegrin
domain in the COS1-transfected cells. Notably, the doublets
result from different forms of glycosylation as verified by gly-
cosidase F treatment (Ref. 46 and data not shown). To probe
the domain in which the processing occurs, we made two dele-
tion forms of hADAM19 with C-terminal FLAG tags, soluble
hADAM19 (D52), which lacked the transmembrane domain
and cytoplasmic domain, and a form that lacked the cysteine-
rich domain through the cytoplasmic domain (D-CR) (see Fig.
4). When D52 and D-CR were transfected into COS1 cells, we
were able to detect several proteins in the conditioned media
using both anti-FLAG-M2 and the antibody against the disin-
tegrin domain, including the soluble pro and active forms of
hADAM19. However, a 26-kDa protein in the conditioned me-
dium from D52-transfected cells was clearly detectable using
anti-FLAG-M2, but not the disintegrin domain antibody, sug-
gesting that the 26-kDa protein is the processed C-terminal
fragment of soluble hADAM19. In contrast, a doublet at 60–65
kDa was detected in the medium by the anti-disintegrin do-
main antibody, but not anti-FLAG-M2, indicating that the 60-
to 65-kDa protein is the processed N-terminal fragment of
soluble hADAM19 (Fig. 1B). There were no additional proteins
detectable in the conditioned medium from the cells transfected
with D-CR (data not shown); therefore, the processing of
hADAM19 might be accounted for by shedding within its cys-
teine-rich domain.
PMA Up-regulates Processing of Full-length but Not Soluble
hADAM19—PMA is a potent inducer of ectodomain shedding
of many transmembrane proteins (5, 8–12, 14, 16, 19, 20, 34).
To examine the effect of PMA on the processing of hADAM19,
the COS1 cells transfected with F46 were treated with PMA
overnight. As shown in Fig. 2A, PMA obviously enhanced
hADAM19 processing in the COS1-transfected cells as detected
under reducing conditions. Interestingly, we failed to detect the
FIG. 1. hADAM19 is processed
within the cysteine-rich domain in
COS1-transfected cells. A, detection of
hADAM19 by Western blotting with anti-
FLAG-M2 mAb (lanes 1 and 2), anti-cat-
alytic domain pAb (Anti-Cat) (lanes 3 and
4), or anti-disintegrin domain polyclonal
antibody (Anti-Dis) (lanes 5 and 6). Cell
lysates with radioimmune precipitation
assay buffer from COS1 cells transfected
with the blank vector (lanes 1, 3, and 5) or
pCR3.1hADAM19 (F46) (lanes 2, 4, and
6). The pro, active, and processed forms of
hADAM19 are indicated. B, characteriza-
tion of soluble hADAM19. COS1 cells
were transfected with the blank vector
(lanes 1 and 3) or soluble hADAM19 (D52)
(lanes 2 and 4). The conditioned media
were analyzed by Western blotting using
anti-disintegrin domain Ab (Anti-Dis)
(lanes 1 and 2) and anti-FLAG-M2 mAb
(lanes 3 and 4).
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processed N-terminal fragments in the conditioned media from
the F46-transfected COS1 cells, even after PMA treatment
(data not shown), suggesting that the processed N-terminal
fragment may be still associated with the remaining C-termi-
nal fragment or full-length of hADAM19 via one or more disul-
fide bonds. Therefore, according to the definition of ectodomain
shedding, membrane-bound proteins release their soluble
forms and the processing of hADAM19 within its cysteine-rich
domain is not technically a form of shedding. To test if PMA-
enhanced processing relies on the transmembrane and cyto-
plasmic domains, we treated the COS1 cells expressing D52
with PMA. As shown in Fig. 2B, PMA had a negligible effect on
the processing of soluble hADAM19, suggesting that PMA
might enhance the processing of hADAM19 via interaction
with the cytoplasmic domain, transmembrane domain, or both.
As a note, we used the processed C-terminal fragment at 26
kDa as a marker for the processing of soluble hADAM19
throughout this study.
The Processing at Glu586 2 Ser587 within the Cysteine-rich
Domain Occurs by an Autolytic Mechanism—A recent report
showed that ADAM13 shedding is dependent on its own met-
alloproteinase activity (48). We therefore hypothesized that the
metalloproteinase activity of hADAM19 is also involved in its
processing. To test this hypothesis, we used several independ-
ent approaches. As shown in Fig. 3A, rare processing was
detected in the conditioned media from D52-transfected COS1
cells that were treated with decRVKR-CMK, which blocks the
activation of hADAM19 (46). This indicates that prodomain
removal is necessary for the processing at its cysteine-rich
domain of hADAM19. Furthermore, 199RA-D, an inactive mu-
tant of soluble hADAM19 resistant to furin-mediated removal
of its prodomain (46), displayed no processing, confirming that
the soluble pro-form of hADAM19 lacks the capacity to process
at its cysteine-rich domain (Fig. 3A). (The total protein level in
the media was comparable to that in the media of the D52
cells.) We also generated another soluble inactive form of
hADAM19 (E346A-D), in which the active residue Glu at 346 in
the metalloproteinase domain was mutated to Ala, and trans-
fected it into COS1 cells. Obviously, no processing at its cys-
teine-rich domain was observed in the media of these cells.
Once again, the total protein level in the media was almost
equal to that in the media of the D52 cells (Fig. 3A). These
results strongly argue that the processing at its cysteine-rich
domain of soluble hADAM19 depends on its own metallopro-
teinase activity. However, neither GM6001 nor TIMP-3, inhib-
itors that typically block sheddase activity (26–30), inhibited
the autolytic processing of hADAM19 at its cysteine-rich do-
main (data not shown).
To further confirm that autolytic processing at its cysteine-
rich domain occurs in soluble hADAM19, we generated stable
MDCK cell lines called D52-5, 199RA-D-6, and E346A-D-17,
which expressed soluble D52, 199RA, and E346A, respectively.
As we expected, the 26-kDa-processed fragment was clearly
detectable in the conditioned media from D52-5; the processing
was dramatically inhibited by decRVKR-CMK (Fig. 3B). Fur-
thermore, there was no processing at the cysteine-rich domain
in 199RA-D-6 and E346A-D-17 (Fig. 3B). (The total amount of
soluble protein was comparable among the conditioned media
of these cell lines). Once again, PMA, GM6001, and TIMP-3
failed to affect the processing of D52-5 (Figs. 2B and 3B, data
not shown).
N-terminal sequencing revealed that the starting sequence
of the purified 26-kDa protein was SNAVPIDT, which is iden-
tical to 596SNAVPIDT594 within the cysteine-rich domain of
hADAM19. This suggests that the processing of hADAM19
occurs at Glu5862 Ser587 within its cysteine-rich domain (Fig.
3B).
The Sizes of Glu586 and Ser587 Are Critical for the Processing
at Glu586 2 Ser587 of Soluble hADAM19—To examine the
importance of the Glu586 (P1) and Ser587 (P1) sites in the
processing at Glu586 2 Ser587 of soluble hADAM19, we
changed the size, charge, and polarity of these two residues by
mutagenesis. The constructs are shown in Fig. 4. Shown in Fig.
5A, there was no or little detectable processing in the COS1
cells transfected with either E586D-D or S587T-D, suggesting
that subtle changes in the sizes of residues at the P1 and P1
positions can dramatically impair the processing. Furthermore,
rare or little processing was observed when significant changes
were made to the side chains of the residues at these sites, as
in the cases of the Glu586 to Ala or Gly, and Ser587 to Phe
mutants (Fig. 5A). On the other hand, the amount of processing
product in the E586Q-D or S587A-D mutant, in which the side
chain of the amino acid residue was almost the same size as
that in wild type soluble hADAM19, was almost equal (Fig. 5A).
To further confirm the fate of processing at Glu586 2 Ser587
upon changes at the P1 and P1 sites, we chose mutants with
subtle changes and, presumably, structural similarities, Glu586
to Asp and Ser587 to Thr, to generate stable transfectants in
MDCK cells. Shown in Fig. 5B, rare or little processing was
detectable in the conditioned media from these stable MDCK
transfectants, confirming that both soluble E586D-D and
S587T-D have undetectable or little ability to process, even if
they are cleaved by furin in the MDCK transfectants. (There
were no significant differences in protein levels among the
transfectants.)
The Signals of CaM and Calcium May Be Involved in the
Processing at Glu5862 Ser587 of hADAM19—In addition to the
PKC pathway, there are several other signal pathways, involv-
ing tyrosine kinase, MAPKs, phosphatase, phosphatidylinosi-
tol 3-kinase, calcium, and CaM, which regulate the ectodo-
main-shedding process (10, 13–19, 21–23). Specific inhibitors
were used to determine whether or not these signal pathways
regulate the processing at Glu586 2 Ser587 of hADAM19. As
shown in Fig. 6, only CaM inhibitors impaired the processing of
soluble hADAM19. The other inhibitors, including genistein,
PD98059, pervanadate, wortmannin, and LY290042, had no
significant effects on the processing of soluble or full-length
hADAM19 (data not shown). In addition, both A23187 and
brefeldin A block the activation of both soluble and full-length
FIG. 2. PMA enhances the processing at cysteine-rich domain
of full-length, but not soluble, hADAM19. A, enhancement of the
processing at cysteine-rich domain of full-length hADAM19 by PMA.
COS1 cells were transfected with the blank vector (lane 1) or F46 (lanes
2 and 3). After treated without (lanes 1 and 2) or with PMA (50 nM) (lane
3) overnight, the cells were lysed and probed with anti-FLAG-M2 mAb.
B, PMA had no effect on the processing at cysteine-rich domain of
soluble hADAM19. The conditioned media were collected from COS1
cells transfected with the blank vector (lane 1) or D52 (lanes 2 and 3)
after overnight treatment with 50 nM PMA. The results were obtained
from Western blots using anti-FLAG-M2 mAb.
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hADAM19 (46). There was no processing at Glu586 2 Ser587
detectable under the treatment of either A23187 or brefeldin A
(data not shown), indicating that hADAM19 is activated and
processed in the secretory pathway. Taken together, our re-
sults suggest that PKC, CaM, and calcium signal pathways
may be related to the processing at Glu586 2 Ser587 of
hADAM19.
The Processing at Glu5862 Ser587 Is Necessary for hADAM19
to Exert Its Proteolytic Activity against 2-M—To assess the
significance of the processing at Glu5862 Ser587 of hADAM19,
we purified the proteins from D52-5, E586D-D, and S587T-D,
respectively. Intriguingly, the processed N-terminal fragments,
containing the metalloproteinase, disintegrin, and parts of the
cysteine-rich domain, were detected as mature forms using
anti-disintegrin antibody (data not shown). This suggests that
the processed N-terminal segments bind with unprocessed sol-
uble forms or processed C-terminal-soluble fragments by one or
more disulfide bonds, consistent with the results obtained early
from the full-length hADAM19 (data not shown). When we
probed the purified proteins with anti-FLAG-M2, as shown in
Fig. 7A, S587T-D displayed relatively more processing than
E586D-D, in which a very low level of processing was detected.
D52-5 showed much more processing than E586D-D and
S587T-D. As shown in Fig. 7B, D52-5 protein had a much
greater ability to form a complex with 2-M and generate two
products compared with both E586D-D and S587T-D proteins,
which displayed much lower activities. Obviously, S587T-D
had a relatively higher activity than E586D-D, which showed
very low activity. These results perfectly coincide with the
Western blot shown in Fig. 7A, indicating that the more that
hADAM19 processed at Glu586 2 Ser587, the more proteolytic
activity it exerted against 2-M in vitro.
Ac-RPLE-SNAV Is Cleaved by Active hADAM19—To test
hADAM19 activity, we synthesized a new peptide, Ac-RPLE-
SNAV, which encompasses the processing site of hADAM19
and is conserved among humans and mice (42, 45). Because the
processing at Glu586 2 Ser587 is mediated by its own metallo-
proteinase activity (Fig. 3), we were able to use this peptide to
assay soluble hADAM19 activity and obtained the similar re-
sults as from the 2-M assay (Fig. 7B). Once again, the highest
FIG. 3. hADAM19 autolytically process at Glu5862 Ser587 within the cysteine-rich domain. A, autolytic processing at the cysteine-rich
domain of soluble hADAM19 in COS1-transfected cells. COS1 cells were transfected with the blank vector (lanes 1), D52 (lanes 2 and 3), soluble
mutant with 199RR to 199AA (199RA-D) (lane 4), or soluble inactive mutant (E346A-D) (lane 5) and incubated without (lanes 1, 2, 4, and 5) or with
100 M CMK (lane 3) for 16 h. The conditioned media were analyzed by Western blotting with anti-FLAG-M2 mAb. B, processing at cysteine-rich
domain of soluble hADAM19 in the stable MDCK transfectants. MDCK cells stably expressing soluble hADAM19 (D52-5) (lanes 2–5), soluble 199RA
mutant (199RA-D-6) (lane 6), or the soluble inactive mutant (E346A-D-17) (lane 7) were treated without (lanes 1, 2, 6, and 7) or with 5 M GM6001
(lane 3), 100 nM TIMP-3 (lane 4), or 100 M CMK (lane 5) overnight. The conditioned media were analyzed by Western blotting using anti-FLAG-M2
mAb. MDCK cells transfected with the blank vector were used as a control (lane 1). The sequence for the shed C-terminal protein is shown at the
bottom.
FIG. 4. A schematic illustration of the wild type expression
vector pCR3.1hADAM19 and its mutant constructs. All of the
constructs have a C-terminal FLAG tag. SP, signal peptide; Pro-, prodo-
main; Cat-, catalytic domain; Dis-, disintegrin domain; Cys-, cysteine-
rich domain; EGF-, EGF-like domain; TM, transmembrane domain;
CD, cytoplasmic domain; F, FLAG tag.
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activity was seen in D52-5 with 1% cleavage after incubation
overnight. E586D-D and S587T-D only showed 30 and 10% the
activity exerted by D52-5, respectively (data not shown). As we
knew, the activity at 1% was not enough for a fluorescence
assay. However, given that D52-5 was not fully processed (may-
be 25% of the mature hADAM19 got processed according to the
Western blotting result as shown in Fig. 7A), we decided to
generate another stable line in MDCK cells expressing D-CR
(Fig. 4). The reason we deleted the whole cysteine-rich domain
is that we surmised that this domain has a potential interac-
tion with the metalloproteinase domain, disintegrin domain, or
both that might decrease the activity. Fortunately, purified
D-CR from the MDCK transfectants had a higher activity for
cleaving our new peptide substrate, and the cleavage product
detected by N-terminal sequencing was peptide SNAV, con-
firming that the peptide substrate was cleaved at the E-S bond,
which is identical to the processing site in the hADAM19 pro-
tein. Furthermore, as shown in Fig. 8, the kcat, Km, and kcat/Km
values for 150-min incubation were 2.4 min1, 2.0 mM, and
1200 M1 min1, respectively. Thus, we developed a peptide
substrate for determining soluble hADAM19 activity by a fluo-
rescamine assay.
DISCUSSION
In the current report, we have demonstrated that processing
of hADAM19 occurs at Glu5862 Ser587 within the cysteine-rich
domain by its own metalloproteinase activity and is a neces-
sary step to display its proteolytic activity against both a pep-
tide substrate and 2-M in vitro. We have also revealed that
the processing at Glu5862 Ser587 of hADAM19 is regulated by
a unique pathway, distinguishable from those shown for other
ADAMs, MT-MMPs, and other membrane-bound proteins.
Shedding or Processing of Metalloproteinases—Growing evi-
dence suggests that shedding is of vital importance for the
regulation of metalloproteinase activity. For MT-MMPs, Pei’s
group reported that MT5-MMP is shed by furin, down-regulat-
ing its activity, and that interleukin-8 triggers the signal for
both release and activation of MT6-MMP by an unknown mech-
anism (47, 52). The activity of MT1-MMP can be autolytically
terminated directly on the cell surface or via production of a
soluble functional fragment, consequently down-regulating en-
zyme activity on the cell surface (40). Among ADAMs, ADAM13
is the only one that has been shown to shed its ectodomain
intracellularly by an autolytic mechanism, producing an active
enzyme able to bind with 2-M and integrins (48). In addition,
truncation of mature ADAMTS4 at its C terminus is required
for its aggrecanase activity (49). In this report, we demonstrate
that hADAM19 carries out processes within its cysteine-rich
domain, resulting in an active enzyme shown by both 2-M and
peptide substrate assays in vitro (Figs. 3, 7, and 8). It might,
therefore, be a general regulatory mechanism that MT-MMPs,
such as MT1-MMP and MT5-MMP, are down-regulated by
shedding to release active forms from the cell surface, whereas
ADAMs must shed, carry out process, or become truncated at
the C terminus to exert their functions, such as acting as a
sheddase, binding with integrins on the cell surface, or digest-
ing components of the extracellular matrix.
Regulation of the Processing at Glu586 2 Ser587 of
hADAM19—The signal pathways involved in shedding or trun-
cation processes, especially of ADAMs, are poorly understood.
In the present report, we provide unique characteristics of the
regulation of the processing at Glu586 2 Ser587 of hADAM19.
We found that PMA, a common inducer of shedding, also en-
hances the processing at Glu586 2 Ser587 of hADAM19 (Fig.
FIG. 5. The residue sizes at both Glu586 and Ser587 are critical
for the processing at Glu586 2 Ser587 of hADAM19. A, processing
profile at Glu5862 Ser587 of soluble mutants in COS1-transfected cells.
COS1 cells were transfected with the blank vector (lane 1), D52 (lane 2),
soluble mutants with Ser587 to Ala (S587A-D) (lane 3), Thr (S587T-D)
(lane 4), or Phe (S587F-D) (lane 5), or Glu5863 Gly (E586G-D) (lane 6),
Ala (E586A-D) (lane 7), Asp (E586D-D) (lane 8), or Gln (E586Q-D) (lane
9). The conditioned media were subjected to SDS-PAGE and Western
blotting with anti-FLAG-M2 mAb. B, detection of the processing at
Glu586 2 Ser587 of hADAM19 in MDCK cells stably expressing soluble
hADAM19 mutants. Four MDCK cells stably expressing soluble
hADAM19 with Glu586 3 Asp (E586D-D-12 and E586D-D-18) (lanes 3
and 4) or Ser587 to Ala (S587A-D-12 and S587A-D-20) (lanes 5 and 6)
were prepared in serum-free media overnight. The conditioned media
were analyzed by Western blotting using anti-FLAG-M2 mAb. MDCK
cells transfected with the blank vector (lane 1) and D52-5 cells (lane 2)
were used as controls.
FIG. 6. Processing at Glu586 2 Ser587 of hADAM19 is inhibited
by calmodulin inhibitors. MDCK cells stably expressing soluble
hADAM19 (D52-5) (lanes 2–5) were treated without (lanes 1 and 2) or
with 100 M trifluoperazine (lane 3), 25 M W7 (lane 4), or 50 M
calmidazolium (lane 5) for 16 h. The conditioned media were then
analyzed by Western blotting using anti-FLAG-M2 mAb. MDCK cells
transfected with the blank vector were used as a control (lane 1).
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2A). The mechanism probably involves the cytoplasmic domain,
transmembrane domain, or both, because PMA did not alter
the processing of soluble hADAM19 (Fig. 2B). This is consistent
with reports showing that the cytoplasmic domain of ADAM9 is
required for PMA-induced shedding (34) and that the mem-
brane anchor of TACE is necessary for its processing of TNF-
(53, 54). In addition, there are a few reports that have demon-
strated the requirement of the cytoplasmic tail for shedding of
pro-NRG, APP, pro-TGF, and L1 adhesion molecules (17, 55,
56). However, in most cases, endogenous and/or inducer-medi-
ated shedding is independent of the cytoplasmic domain (Fig.
2B) (14, 17, 19, 22, 24). Calcium ionophore, A23187, is another
potent inducer of most protein-shedding processes (13–16).
Nevertheless, we found that A23187 and brefeldin A block the
activation of both full-length and soluble hADAM19. Subse-
quently, no processing at Glu5862 Ser587 was detectable, sug-
gesting that hADAM19 is activated and processed in the secre-
tory pathway (46, data not shown). Inhibitors of CaM have
been shown to stimulate the shedding of several proteins, in-
cluding MT1-MMP, pro-TGF, pro-NRG, and APP, by a mech-
anism independent of both PKC and calcium (17–20). However,
in our study, a reverse result was obtained; the processing at
Glu586 2 Ser587 was inhibited by the CaM inhibitors (Fig. 6).
Finally, we found that tyrosine kinase, MAPK, phosphatase, or
phosphatidylinositol 3-kinase do not seem to play roles in the
processing at Glu586 2 Ser587 of hADAM19 (data not shown),
although they have been previously shown to participate in
some shedding processes (9–12, 21–23, 29).
In addition, the proteinases responsible for the shedding of
many cell surface molecules seem to have broad sequence spec-
ificity as revealed by mutational analysis of residues around
the cleavage site of pro-TGF, APP, IL-6 receptor, L-selectin,
and pro-TNF (57–61). In this report, we used mutagenesis to
show that the residue sizes of the side chains at both the Glu586
and Ser587 sites are extremely important for normal processing
at Glu586 2 Ser587 of hADAM19. Even delicate changes, such
as Glu5863 Asp and Ser5873 Thr, caused dramatic decreases
in the processing. Notably, many studies have shown that some
potent synthetic inhibitors of metalloproteinases, such as
TAPI, BB94, and GM6001, can block most, if not all, shedding
processes and that many shedding processes are sensitive to
TIMP-3, a matrix-associated TIMP that preferably inhibits
ADAMs (5–8, 19, 24–30). However, neither GM6001 nor
TIMP-3 inhibits the autolytic processing at Glu586 2 Ser587 of
hADAM19 (Fig. 3B), which is consistent with some reports
showing that the shedding of MT5-MMP, MT6-MMP, and IL-6
receptor is not affected by metalloproteinase inhibitors (47, 52,
62). One possibility, we speculate, is that shedding, in most
cases, occurs at membrane-proximal regions on the cell surface,
which are easily accessible to hydroxamate-based inhibitors
and TIMP-3 (5, 25, 60, 63). Human ADAM19 processing takes
place at a region distal from the transmembrane domain in the
secretory pathway, which is less accessible to GM6001 and
TIMP-3 (Fig. 3B). How hADAM19 initiates the processing at
Glu586 2 Ser587 and what the roles for the disintegrin- and
cysteine-rich domains are during the processing at Glu586 2
Ser587 remain to be uncovered. Perhaps dimerization through
the disintegrin- and/or cysteine-rich domains is the key step for
the processing as proposed for other ADAMs (3). This might
also be an explanation for the fact that the processed N-termi-
nal fragments, containing the metalloproteinase, disintegrin,
and parts of the cysteine-rich domain, were not detected in the
conditioned medium from the transfected COS1 cells with full-
FIG. 7. Requirement of the processing at Glu586 2 Ser587 for
the proteolytic activity of hADAM19. A, processing status at Glu586
2 Ser587 of purified proteins from the stable MDCK transfectants.
MDCK cells stably expressing soluble hADAM19 (D52-5) (lane 2), sol-
uble Glu586 3 Asp (E586D-D-12) (lane 3), or soluble Ser587 to Ala
(S587A-D-20) (lane 4) were prepared for purification as described under
“Materials and Methods.” Western blots using anti-FLAG-M2 mAb
were performed on equal amounts of these purified proteins. B, the
proteolytic activity of soluble hADAM19 using 2-M in vitro. The puri-
fied hADAM19 from D52-5 (lanes 1 and 5), E586D-D-12 (lanes 2 and 6),
or S587A-D-20 (lanes 3 and 7) were normalized and incubated in reac-
tion buffer alone (lanes 1–3) or with 2-M (lanes 5–7) for 24 h. 2-M in
reaction buffer alone (24 h) was a control (lane 3). The 2-MhADAM19
complex and the cleavage products of 2-M by hADAM19 are labeled on
the right.
FIG. 8. The hydrolysis of Ac-RPLE-SNAV by hADAM19. The
peptide (Ac-RPLE-SNAV) (0.2–4.0 mM), which mimics the processing
site of hADAM19, was incubated with 0.26 M soluble, active ADAM19
for 150 min. The formation of product was measured by monitoring the
coupling of fluorescamine with the amino group newly formed from the
cleavage. The nonlinear regression analysis of the data indicates kcat 
2.4 min1, Km  2.0 mM, and kcat/Km  1200 M
1 min1.
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length hADAM19 and were present among the purified soluble
hADAM19 proteins (data not shown).
A New Peptide Substrate Based on the Processing Site Se-
quence for hADAM19—The peptide substrates currently used
to measure MMP activity are synthesized based on the cleav-
age sites of protein substrates. Because hADAM19 processes at
Glu586 2 Ser587 by its own metalloproteinase activity, we sur-
mised that a peptide encompassing the processing site would
be an ideal substrate. Indeed, this peptide, Ac-RPLE-SNAV,
was suitable for a fluorescamine assay of enzyme activity and
was cleaved at the E-S site as determined by peptide N-termi-
nal sequencing. Although the wild type hADAM19 showed a
minimally detectable activity by this method, D-CR, containing
the metalloproteinase and disintegrin domains, displayed a
higher activity to determine kinetic parameters after incuba-
tion for 150 min using our fluorescamine assay (Fig. 8). The
kinetic parameters, kcat, Km, and kcat/Km, were 2.4 min
1, 2.0
mM, and 1200 M1 min1, respectively, demonstrating that this
is a poor substrate and will have a limited usage. It is necessary
that the peptide substrates will be optimized by creating ana-
logs that are hydrolyzed more efficiently by hADAM19 in the
near future. Our preliminary data show that TIMP-3 can in-
hibit hADAM19 activity in this peptide-based assay,2 which is
similar to the results for ADAM10, -12, and -17 and ADAMTS4
and -5 in vitro (64–67), and confirm that the TIMP-3 we used
was active. However, TIMP-3 had no effect on the cellular
processing at Glu586 2 Ser587 of soluble hADAM19 (Fig. 3B),
indicating that this processing occurred intracellularly, to
where TIMP-3 molecules might not be accessible. Interestingly,
ADAMTS4 is truncated at Glu373 2 Ala374, the site for the
cleavage of ADAMTS4 and ADAMTS5, not MMPs. In contrast,
the truncation site at Asn341 2 Phe342 is mediated by MMPs,
not aggrecanases (49, 68). Our mutational data showed that
the Glu586 2 Ala587 processing site was also optimal for auto-
lytic processing of hADAM19 (Fig. 5B), indicating that our
peptide substrate might be useful to determine the activity of
other ADAMs, such as aggrecanases. This peptide substrate
may also be used for testing metalloproteinase inhibitors
against hADAM19 and other ADAMs.
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ABBREVIATIONS 
ADAM, a disintegrin and metalloproteinase; ADAMTS, a disintegrin and metalloproteinase 
with thrombospondin-like motifs; alpha 2-M, alpha-2-macroglobulin; APP, amyloid precursor 
protein; CaM, calmodulin; DMEM, Dulbecco’s modified Eagle´s medium; ECM, 
extracellular matrix; FBS, fetal bovine serum; IL-1R-II , interleukin 1 receptor II;   MDC, 
Metalloprotease/Disintegrin/Cysteine -rich; MDCK, Madin-Darby canine kidney; NRG, 
neuregulin; pAb, polyclonal antibody; PBS, phosphate buffered saline; PKC, protein kinase 
C; PMA, phorbol-12 myristate 13-acetate; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis; TACE, tumor necrosis factor alpha convertase; TIMPs, 
tissue inhibitor of matrix  metalloproteinases; TGF-alpha, transforming growth factor -alpha; 
TGN, trans-Golgi networks; TNF-alpha , tumor necrosis factor-alpha; W7, N-(6-aminohexyl)-
5-chloro-1-naphthalenesulfonamide.  
   
              
 37 
                                                         SUMMARY 
We reported that human adamalysin 19 (a disintegrin and metalloproteinase 19, hADAM19, 
meltrin beta) is activated by furin-mediated cleavage of the prodomain followed by an 
autolytic processing at Glu586-Ser587 within the cysteine-rich domain (Kang et al. J. Biol. 
Chem., 277: 25583-25591 and 48514-48522, 2002). Here we demonstrated that this autolytic 
processing at Glu586-Ser587 occurred intramolecularly, producing an NH2-terminal fragment 
(N-fragment) associated with its COOH-terminal fragment (C-fragment) through disulfide 
bonds. Cys605, Cys633, Cys639 , and Cys643 within the residual cysteine-rich domain of the C-
fragment are partially responsible for the covalent association of the C-fragment with the N-
fragment. A new processing site at Lys 543-Val544 was identified in soluble mutants when these 
cysteine residues were individually mutated to serine residues. These mutated proteins were 
folded, secreted, and had enzymatic activity, but were less stable and more easily degraded 
than the soluble wild type, as illustrated by trypsin digestion and inactive mutant studies. The 
proteolytic activity and the stability of soluble hADAM19 may be regulated by the formation 
of disulfide bonds between cysteine residues within the N-fragment and C605, C633 , C639, and 
C643 at the C-fragment. Moreover, the new processing site resulted from autolytic cleavage 
was independent of the processing at Glu586-Ser587 by utilizing the double mutations of 
Cys633Ser/Glu586Asp or Cys639Ser/Glu586Asp. Shed fragments are also detectable in the 
media from Madin-Darby canine kidney cells stably expressing the full length Cys633Ser 
mutant. Ilomastat (GM6001), a potent matrix metalloproteinase inhibitor, only had little effect 
on the shedding process although it inhibited digestion of a peptide substrate by purified 
hADAM19, suggesting that this shedding process may be an intracellular event. Thus, the 
cysteine-rich domain may regulate the enzyme stability and activity of ADAMs via the 
formation of inter-fragment disulfide bond(s). 
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                                                                 INTRODUCTION 
      Ectodomain shedding, a process by which transmembrane proteins proteolytically release 
their extracellular domains, plays a critical role in many physiological and pathological 
conditions (1-3). Numerous studies have shown that ADAMs (A Disintegrin And 
Metalloprotease), also called adamalysin/ MDC (Metalloprotease, Disintegrin, Cysteine-rich), 
such as ADAM17/TACE, ADAM10/Kuzbanian (KUZ), ADAM9, ADAM19/MDC beta??and 
ADAM12/MDC alpha , are the predominant sheddases responsible for the shedding of most 
molecules identified so far, such as tumor necrosis factor -alpha (TNF-alpha), transforming 
growth factor-alpha (TGF-alpha ), interleukin 1 receptor II (IL-1R-II) , Notch and its ligand 
Delta, amyloid precursor protein (APP), heparin-binding epidermal growth factor (HB-EGF), 
mucin MUC1, and neuregulin-beta?(NRG-beta1) (3-5). The activities  of ADAMs are 
regulated at multiple levels including transcription, translation, zymogen activation, and 
inhibition by tissue inhibitors of matrix  metalloproteinases (TIMPs) (2-6). The principle 
regulatory step is zymogen activation, which has been attractive to a number of investigators 
with the predominant focus on the regulation rela ted to prodomain removal (6-18). 
Synthesized as zymogens, ADAMs must undergo prodomain cleavage by either furin or furin-
like proprotein convertases before they display any proteolytic activities, as in the cases of 
ADAM1, 9, 12, 15, 17, 19, a disintegrin and metalloproteinase with thrombospondin 1-like 
motifs (ADAM-TS) 1, 4, 12, (6-16), or by autolysis, as seen in ADAM8 (17) and ADAM28 
(18). However, in some ADAMs, the prodomains have functions involved in their catalytic 
activities. For example, deletion of the prodomain destroys the proteolytic activity of 
ADAM10 (19, 20). In the cases of ADAM12 and 17, the prodomains are not only an inhibitor 
of the catalytic domain, but also appear to act like a chaperone, facilitating secretion, folding, 
or both for the ADAM proteins (12, 21). In addition, many mutations interfere with the 
folding or processing of ADAMs, resulting in a lack of proteolytic processing. For instance, 
the cysteine residue replaced with alanine in the prodomain of ADAM9 abolished its 
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prodomain removal (12); both His346 and His350 substitutions with alanines in the 
metalloproteinase domain of mouse ADAM19 abrogated the processing of its prodomain 
(22); the L73P mutant of ADAM12 resulted in complete retention of ADAM12 in the 
endoplasmic reticulum (ER) and inhibition of its processing (14); the soluble form of 
ADAM13 has never been converted into its mature form, indicating that the transmembrane 
domain, cytoplasmic domain, or both, are indispensable for the processing of the prodomain 
in ADAM13 (23); the removal of the disintegrin and cysteine-rich domains in the tumor 
necrosis factor-alpha converting enzyme (TACE)/ADAM17 resulted in secretion of the 
mature catalytic domain in association with the precursor (pro) domain, demonstrating that 
the disintegrin and cysteine-rich domains appear to play a role in the release of the prodomain 
(21).  
          Most recently, there is increasing evidence showing that C -terminal truncation plays a 
critical role in the regulation of the proteolytic activity of ADAMs, as illustrated by ADAM8, 
13, and 19, and ADAM-TS4 (16, 17, 23-25). This truncation produces active enzymes or 
functional fragments to exert their functions, such as acting as sheddases, binding with 
integrins on the cell surface, or digesting components of the extracellular matrix (ECM) (16, 
17, 23-25). However, the regulation of this processing remains to be uncovered. Intriguingly, 
Smith et al. showed that the cysteine -rich domain affects the proteolytic activity of ADAM13 
in vivo , probably by an intramolecular interaction with its metalloproteinase domain, and that 
this model might be applied to other ADAMs (26). This prompted us to explore how this 
intramolecular interaction occurs in ADAMs, since we demonstrated that an autolytic 
processing of hADAM19 at E586-S 587 within the cysteine-rich domain takes place in the 
secretory pathway (24). Based on the fact that the E586-S587 processed active N-fragment 
containing metalloproteinase and disintegrin domains and a segment of the cysteine-rich 
domain is not released from the C-fragment containing the C-terminal part of the cysteine-rich 
domain and epidermal growth factor (EGF)-like domain under non-reducing conditions (24), 
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we hypothesized that interfragment disulfide bond(s) may play a crucial role in the processing 
of hADAM19. This report provides evidence that a critical role in the stability of the 
processed hADAM19 is played by disulfide bonds formed between cysteine residues in the N-
fragment and those in the segment of the cysteine -rich domain of the processed C-fragment. 
 
                             MATERIALS AND METHODS 
Chemicals, Cell Lines, Cell Culture, and Immunological Reagents---All common laboratory 
chemicals, proteinase inhibitors, phorbol-12 myristate 13-acetate (PMA), N-(6-aminohexyl) -
5-chloro-1-naphthalenesulphonamide (W7),  trypsin, soybean trypsin inhibitor, and anti-
FLAG-M2 monoclonal antibody and its agarose conjugates were purchased from Sigma (St. 
Louis, MO). A matrix metalloproteinase inhibitor , Ilomastat (GM6001), was purchased from 
BACHEM (Philadephia, PA). Restriction enzymes were purchased from Promega (Madison, 
WI) or Invitrogen (Gaithersburg, MD). COS1, Madin Darby canine kidney (MDCK) cells and 
its derivatives were maintained as described (13, 24). Dulbecco's modified Eagle's medium 
(DMEM) was purchased from Invitrogen Gibco BRL (Gaithersburg, MD). Fetal bovine serum 
(FBS), penicillin G, and streptomycin were purchased from Life Technologies (Rockville, 
MD). alpha2-macroglobulin (alpha 2-M) was purchased from Roche Molecular Biochemicals 
(Indianapolis, IN). Rabbit polyclonal hADAM19 antibody pAb361 (anti-metalloproteinase 
domain, anti-Cat) was generated by our laboratory as reported (27).   
Polymerase Chain Reaction (PCR) Primers, Mutagenesis, and Expression Constructs---All 
inserts tagged with FLAG at their C-terminus were cloned into pCR3.1uni, including wild 
type hADAM19 (F46), soluble hADAM19 (D52), D-E346A, D-E586D, D-CR (described in 
Ref. 24), and all mutants used in this study. For D586 deleted from S587 to the end of the C-
terminal: forward primer, 5’- ACC ATG CCA GGG GGC GCA GGC GCC-3’; reverse 
primer, 5’- CTC CAG GGG CCG GGC CTC AGA G -3’.  For the soluble  C605 to S 605 
mutants (D-C605S): forward primer, 5’- CAG ATC CAG TCC CGG GGC ACC CAC-3’; 
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reverse primer, 5’- GGT GCC CCG GGA CTG GAT CTG CC-3’. For the full length and 
soluble C633 to S633 mutants (F-C633S and D-C633S): forward primer, 5’- GGA ACC AAG 
TCT  GGC TAC AAC C-3’; reverse primer, 5’- GTT GTA GCC AG A CTT GGT TCC 
AG-3’. For the soluble C 639 to S639 mutant (D-C639S): forward primer, 5’- C AAC CAT ATT 
TCC TTT GAG GGG CAG-3’; reverse primer, 5’- CCC CTC AAA GGA AAT ATG GTT 
G-3’. For the full length and soluble C643 to S643 mutants (F-C643S and D-C643S): forward 
primer, 5’- GAG GGG CAG TCC AGG AAC ACC TC-3’; reverse primer, 5’- GGT GTT 
CCT GGA CTG CCC CTC AAA G-3’. For the double mutants, including E586 to D586 and 
C633 to S633 (D-C633S/E586D), E586 to D586 and C639 to S639 (D-C639S/E586D), E346 to A346 
and C633 to S633 (F- C633S/E346A and D-C633S/E346A), and E346 to A346 and C643 to S643 (F- 
C643S/E346A and D-C643S/E346A), we used D-E586D or D -E346A as the template and the 
primers for C633 to S633 or C639 to S639, respectively. All constructs were confirmed by DNA 
sequencing.   
DNA Transfection and  Generation of Stable Cell Lines---COS1 cells were seeded in 24-well 
plates for 16-24 hrs at 80% confluence and transfected or co-transfected with the indicated 
plasmids using LipofectAMINE2000 according to the instructions provided by Invitrogen 
(Gaithersburg, MD). After 6-10 hrs, serum-free DMEM media and the indicated reagents 
were added and incubated for another 24 hrs. The conditioned media and cell lysates were 
then analyzed by Western blotting (13, 24). The same transfection procedure was performed 
to generate stable MDCK cell lines, and the selection for hADAM19 was begun in the 
presence of G418 (400 ug/ml) after transfection for 24 hours. The conditioned media and/or 
cell lysates of the clones were subjected to Western blotting to confirm the expression of 
hADAM19 (13, 24). For co-culture cells, the indicated MDCK stable lines were equally 
mixed in the same wells overnight, followed by serum-free media for 24 hours, and the media 
were then analyzed by Western blotting. 
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Western Blotting----The experiments were carried out as described previously (13, 24). 
Briefly, cells were grown to 80% confluence and were treated as indicated. After 
centrifugation for 15 mins at 14,000 x g  and 4ºC to clear any debris, the serum-free media 
were collected and prepared for SDS-PAGE. The  cells were lysed with RIPA buffer (50 mM 
Tris, pH 7.5, 150 mM NaCl, 0.25% sodium deoxycholate, 0.1% NP-40, 1 mM phenyl-methyl-
sulfonyl-fluoride, 1 mM of 1, 10-phenasrol, 10 ug/ml aprotinin, 10 ug/ml E64, and 10 ug/ml 
pepstatin A) for 15 min on ice. The supernatant was collected after centrifugation for 20 min 
at 14,000 x g and 4ºC. After electrophoresis, the proteins were transferred onto nitrocellulose 
membranes, probed with anti-FLAG-M2 or anti-Dis, and developed as before (13, 24). 
Purification of Soluble hADAM19 and Co -incubation with Purified Proteins--- The proteins 
of D-CR and D -E346A were produced earlier in our laboratory, all proteins were purified on 
anti-FLAG-M2 affinity columns as described previously (24). Briefly, cells from stable lines 
expr essing soluble hADAM19, D586, D-C633S, or D-C633S/E586D, were grown to 100% 
confluence, washed twice with phosphate buffered saline (PBS), and incubated for 48 hours in 
serum-free media. The conditioned media were collected, centrifuged to clear any debris, and 
loaded onto an anti-M2 immunoaffinity column (1 ml of resuspended agarose) that had been 
prewashed with HEPES buffer. The bound materials were extensively washed with HEPES 
buffer, eluted with FLAG peptides , and collected in 500 ul fractions. The fractions were 
analyzed by Western blot using anti-hADAM19 antibodies or anti-FLAG-M2, and the protein 
concentration was quantified by absorbance at 280 nm. The fraction containing the highest 
interested proteins was characterized by protein N -terminal sequencing as described 
previously (13, 24), and the fractions containing the most wild type or mutant hADAM19 
proteins were used for the flourescamine assay or the co-incubation of purified proteins to test 
substrate cleavage. For the co-incubation of purified proteins, we mixed the purified protein 
of D-E346A with D -CR or D586 equally at 100 ng/ ul overnight, then the processing of D-
E346A by D-CR or D586 was detected by Western blotting with Anti-FLAG-M2 as above. 
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Trypsin Digestion Experiment---The protocol followed was from a report by Dr. Bond’s 
group (28). Briefly, Trypsin was added to the conditioned media from D -52-5, D-C633S-4, or 
D586 at a final concentration of 5, 10, 20, or 40 ng/ul in 20 mM Tris-HCl, pH 7.5. After 
incubation at 37ºC for 30 min, soybean trypsin inhibitor was added at a 2-fold excess of 
trypsin. Samples were incubated at 25ºC for 15 min, followed immediately by Western 
blotting using anti-FLAG-M2.  
Determination of the Activity of hADAM19 Using a Peptide Assay---Procedural details were 
described previously (24). Stock solutions of the peptide substrates at 20 mM were prepared 
in 0.05 M HEPES, pH 7.5, 0.2 M NaCl, 0.01 M CaCl2, and 0.01% Brij-35, and the enzyme 
concentration was about 160 nM. Hydrolysis of the peptide by the enzyme following 
incubation for 2.5 hours was monitored by measuring fluorescence intensity using 
fluorescamine assay.   
 
 
RESULTS 
Autolytic Processing at E586-S587 of hADAM19 is an Intramolecular Interaction. We recently 
developed a peptide substrate to determine the activity of hADAM19 by a fluorescamine 
assay, and reported that the autolytic process ing at E 586-S587 within the cysteine-rich domain is 
necessary for its proteolytic activities against both this peptide substrate and ? 2-M (24). To 
directly prove that the processed N-fragment, containing metalloproteinases and disintegrin 
domains and a part of the cysteine-rich domain, is active, we generated a truncated form of 
hADAM19, from the beginning to E586 and tagged with C-terminal FLAG tag (D586) (see 
Fig. 3), which was found to have the same activity as D-CR against this peptide substrate (24, 
data not shown). To determine if processing at E586-S587 of hADAM19 is an inter- or intra- 
molecular interaction, we used several independent approaches. As shown in Fig. 1, the 
inactive soluble hADAM19 (D-E346A) (24) was not processed by either one of its active 
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soluble forms, D586 and D-CR, when co-cultured with their stably-expressing MDCK cells, 
suggesting that the process ing at E 586-S587 of hADAM19 is an intramolecular interaction. 
Furthermore, either D586 or D-CR failed to process D-E346A when we performed a transient 
co-transfection using D-E346A with either D586 or D-CR in COS1 cells, or incubated their 
purified proteins in vitro  using D-E346A with D586 or D-CR (data not shown).  These results 
strongly argue that an intramolecular interaction results in the process ing of hADAM19 at 
E586-S587.  
Disulfide Bonds are Responsible for the Association of the N-fragment with the C-fragment 
Processed at E586-S587 of hADAM19. We have previously suggested that the processed N-
fragment at E586-S587 of hADAM19 may be associated with its processed C -fragment via one 
or more disulfide bonds (24). To further explore this possibility, we ran the conditioned media 
from MDCK cells stably expressing D52 (D52-5) side by side under either reducing or non-
reducing condition. As showed in Fig. 2A and 2B, the mature forms of hADAM19 were 
detected under both reducing and non-reducing conditions. However, the fragment at 26 kDa 
representing the processed C-fragment at E586-S587 of hADAM19 was detectable only under 
reducing condition (Fig. 2A). Moreover, the processed N-fragments emerged together with 
the mature forms under non-reducing conditions (Fig. 2B). Therefore, we may draw the 
conclusion that the processed C-fragment containing a part of the cysteine-rich domain and 
EGF-like domain forms disulfide bonds with the processed N-fragment including 
metalloproteinase and disintegrin domains and a segment of the cysteine-rich domain, in 
soluble hADAM19.  
Since the process ing at E 586-S587 of hADAM19 is an intramolecular interaction (Fig. 
1), and the proteolytic activity of ADAM13 has recently been shown to be regulated by its 
cysteine-rich domain through intramolecular functioning with its metalloproteinase domain 
(26), we hypothesized that the disulfide bonds formed by the cysteine residues of the N-
fragment and those within the part of the cysteine -rich domain retained by the processed C-
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fragment may play a critica l role in the processing of hADAM19 at E586-S587. To evaluate 
this, we mutated the cysteine residues at C 605, C633, C639, and C643 to S605, S633, S639, and S643 
within this region of soluble hADAM19, respectively (Fig. 3), then transiently transfected 
these mutants into COS1 cells. The results shown in Fig. 2C revealed that all mutants 
produced a new C-fragment at around 32 kDa, while the normal processing of the 26 kDa 
fragment at E586-S587 remained unchanged in the mutants with C605 , C633, and C639 to S605, 
S633 , and S639, respectively.  However, the levels of both 26 and 32 kDa fragments in the 
mutant of C643 to S643 were decreased dramatically. When running these samples under non-
reducing conditions, we found that the processed C-fragments at 26 and 32 kDa were not 
associated with their processed N-fragments, suggesting that the association of the N-
fragment with the C-fragment of hADAM19 processed at E586-S587 was destroyed by the 
disruption of one or more disulfide bonds formed between any cysteine residue at C605 , C633 , 
C639 , or C643 and a cysteine residue(s) in the N-fragment.   
 Disulfide Bonds Linked by C605, C 633, C 639 or C 643 and Cysteine Residues in the N-fragment 
are Involved in the Stability of Soluble hADAM19 . To further investigate the functions of 
different disulfide bonds that include C605 , C633, C639, or C643, we generated MDCK cells 
stably expressing the soluble mutants of C 605, C633, C639, and C643 to S605, S633, S639, and S643, 
called D-C605S, D-C633S, D-C639S, and D-C643S, respectively. As shown in Fig. 4A, a 
high expression of soluble hADAM19 was detected in the cell lysates from D-C643S, but the 
proteins in the media contained negligible mature or processed forms of soluble hADAM19, 
indicating that the proteins expressed by D -C643S are not folded or secreted properly, or are 
less stable and more easily degraded when the disulfide bond formed between C 643 and a 
cysteine residue at N-fragment is destroyed. However, aside from the mature forms, we also 
detected the fragments at 26 and 32 kDa by anti-FLAG-M2 in the media from D-C605S, D-
C633S, and D-C639S at different levels (Fig. 4A). Once again, the protein expression level of 
D-C633S is the highest among the mutants, consistent with the results obtained in the COS1 
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transient transfection as shown in Fig. 2C, suggesting that the proteins of D-C633S, D-C639S, 
and D-C605S are more stable and more difficult to degrade, or have fewer problems related to 
folding and secretion than the proteins of D-C643S.  However, c ompared with proteins from 
the soluble wild type hADAM19, lower levels of hADAM19 were detectable in the media 
from D-C633S, D-C639S and D-C605S. The protein levels among these transfects were 
comparable as shown in Fig. 4A, indicating that the disulfide bonds formed between cysteine 
residues at N-fragment and one or more cysteine residues at C 605, C633, C639, and C 643 play 
different roles in soluble hADAM19.  
We chose D-C633S and D-C643S as representatives to generate inactive enzymes, in 
which a catalytic residue E346 was mutated to A346. As shown in Fig. 4B, the protein levels in 
the media from MDCK cells stably expressing both double mutants, D-C633S/E346A and D -
C643S/E346A, were comparable with those in the media from cells expressing the soluble 
inactive form (D-E346A), demonstrating that the disruption of one or more disulfide bonds 
formed between cysteine residues in N-fragment and one or more cysteine residues of C605, 
C633 , C639 , and C643 within the cysteine-rich domain does not disturb the folding and secretion 
of soluble hADAM19. Taken together, we speculate that soluble hADAM19 is stabilized and 
prevented from its autolysis by one or more interfragment disulfide bonds formed between 
cysteine residues at N-fragment and one or more cysteine residues at C605, C633 , C639 , and 
C643. 
To further confirm above speculation related to the function of these cysteine residues 
within the part of the cystein-rich domain retained by the C-fragment processed at E586-S587 of 
soluble hADAM19, we tested the susceptibility of these soluble hADAM19 mutants to 
trypsin digestion, as used in the case of meprin A (28), which showed that cysteine mutants in 
the MAM domain of meprin A were more susceptible to activation by trypsin. The medium of 
D-C633S-4, containing the highest expression level of mature and processed forms of 
hADAM19 among the stable lines (Fig. 4A), was chosen for comparison with soluble 
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hADAM19, D52-5. As shown in Fig. 5, the products of the trypsin digestion in the medium 
from D52-5 were more stable than those from D-C633S-4, suggesting again that one or more 
mutated cysteines in this region may result in less stability or more vulnerability to the 
degradation of soluble hADAM19. This conclusion was further supported by another 
experiment using the protein of D586, which lacked the C-fragment processed at E586-S587 of 
hADAM19 and was more susceptibility to trypsin digestion than D52-5 (Fig. 5). Considered 
together, our results suggest that one or more of the interfragment disulfide bonds formed 
between cysteine residues at the N-fragment and one or more cysteine residues at C605, C633 , 
C639 , and C643 accounts for much of the stability of hADAM19.  Less stability and more 
degradation, but not incorrect folding and secretion, of these mutated proteins, may be 
responsible for the decreased levels of mature or processed forms of soluble hADAM19 
detected in the media from the MDCK cells stably transfected with these Cys to Ser mutants. 
The New Processing at K543-V544 is Independent of the Processing at E586-S587.  Since the 
autolytic processing at E586-S587 of soluble hADAM19 is necessary for its proteolytic activity 
(24), and the new processing is also an autolysis (Fig. 4B), it was very intriguing to determine 
if this new processing is dependent of the processing at E586-S587. To address this issue, we 
made two soluble double mutants, C633 to S633 and E 586 to D586 (D-C633S/E586D), and C639 to 
S639 and E 586 to D 586 (D-C639S/E586D) (Fig. 3) because there was rare processing at E586-S587 
when E 586 was mutated to D586 as described in our previous report (24). We then performed 
transient transfection with these mutants into COS1 cells. As shown in Fig. 6A, the protein at 
32 kDa was detectable in these double mutants, although the protein at 26 kDa, representing 
the processing at E586-S587, disappeared in these media, suggesting that the new processing is 
independent of, but not followed by, the processing at E586-S587. This independence was 
further confirmed when we generated MDCK cells stably expressing the soluble double 
mutants of D-C633S/E586D, as shown in Fig. 6B. To determine the new peptide bond 
cleavage site, we chose one stable MDCK transfectant, D -C633S/E586D -9, as the 
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representative to purify the proteins from their media by anti-FLAG-M2 affinity column and 
electrophoresis.  N-terminal sequencing revealed that the starting sequence of the purified 32 
kDa protein was VNVAGDT, which is identical to 544VNVAGDT within the cysteine-rich 
domain of hADAM19. This suggests that the processing of hADAM19 at K543-V544 is an 
alternative site within its cysteine-rich domain when the primary site at E587-S587 is impaired 
dramatically or its intramolecular disulfide bonds are destroyed. 
The Shedding is Detectable in the Full Length of hADAM19 with C 633 to S 633, and This 
Shedding is Regulated by Protein Kinase C (PKC), calmodulin (CaM), and Calcium Signals. 
Based upon the results shown in Figs. 2C, 4A, and 6, the shedding ability of the full length 
mutants with Cys to Ser was further examined by choosing C633 to S633 (F-C633S) and C643 to 
S643 (F-C643S) as representatives with different stabilities. As shown in Fig. 7A, three shed 
proteins around 44~53 kDa were clearly detected in the media from the MDCK cells stably 
transfected with F-C633S, but neither with the wild type (F46) nor with F-C643S. Expression 
levels were comparable among these stable transfectants, consistent with the results obtained 
earlier with their soluble forms (Figs. 2C, 4A). The double mutants F-C633S/E346A also 
failed to shed (data not shown), demonstrating that F-C633S undergoes autolytic shedding. 
Moreover, we revealed that phorbol-12-myristate 13-acetate (PMA), a PKC activator, 
apparently enhanced the shedding of full length hADAM19 with C633 to S633 , and that W7, an 
inhibitor of CaM, and A23187, a calcium ionophore, inhibited this shedding, consistent with 
our recent report showing that PKC, CaM and calcium signal pathways may be involved in 
the processing of hADAM19 at E586-S587 (24). A potent and broad-spectrum matrix 
metalloproteinase inhibitor, Ilomastate (GM6001), had only little effect on the shedding of 
MDCK cells stably expressing F-C633S of hADAM19 (Fig. 7B) although it was a blocker of 
many shedding processes (3, 29).  Interestingly, GM6001 was able to dramatically inhibit the 
activity of soluble hADAM19 against our peptide substrate used previously (24, data not 
shown), indicating GM6001 was not easily accessible to the intracellular environment during 
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the shedding process. Our current results also support the concept that the processing of 
hADAM19 at E586-S587 takes place intracellularly (24).  
 
DISCUSSION 
      In this current report, w e provide evidence that any one of the cysteine residues within the 
fraction of the cysteine-rich domain of the C-fragment of hADAM19 processed at E586-S587 is 
indispensable for the association of the processed N-terminal with its C-terminal, and plays a 
critical role in the stability of hADAM19. This may lead the first report that the cysteine-rich 
domain likely forms disulfide bonds to regulate the proteolytic activity of ADAMs in vitro. 
     Significance of Autolytic Processing or Shedding in hADAM19. Among ADAMs, 
ADAM8, 13, 19 and ADAM-TS4 have been shown to be processed intracellularly by 
autolysis (16, 17, 23-25), producing an active enzyme or a functional fragment responsible for 
binding w ith alpha2-M or integrins, mediating cell adhesion, or digesting components in the 
ECM. Following our previous report (24), we have demonstrated in this report that 
hADAM19 processing or shedding occurs at a different site, K 543-V544, within its cysteine -
rich domain, which is prior to the normal processing site at E586-S587, under certain conditions, 
as in the case of the disruption of disulfide bonds by mutation or reduction. This also produces 
an active enzyme, as shown in Figs. 2C, 4A, 6, and 7, because the processing or shedding of 
hADAM19 depends on its own proteolytic activity (Fig. 4B, and Ref. 24), but is independent 
of the normal processing at E586-S587 (Fig. 6). Notably, the processing site of E586-S587 is the 
predominant one even in the case of the disruption of the intramolecular disulfide bonds (Fig. 
2A, 4C, 6). However, the site of K543-V544 become the major one when the intramolecular 
disulfide bonds are destroyed and its primary site is mutated (Fig. 6). Given that the 
processing at E586-S587 within the cysteine-rich domain is necessary for its proteolytic 
activities (24), we speculate that there is an alternative site, such as K543-V544, for the 
processing or shedding of hADAM19 within the cysteine-rich domain to produce a fully 
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activated hA DAM19, indicative of its very important roles in both physiological and 
pathological conditions.  
       The Functions of the Cysteine-rich Domain in ADAMs. The “cysteine-rich domain” is 
sometimes referred to the cysteine-rich domain together with the disintegrin domain. In these 
cases, the “cysteine-rich domain” has been shown to be related to cell adhesion, such as in the 
cases of ADAM8, 12, 13, or to the proteolytic activity of TACE/ADAM17. For example, the 
recombinant disintegrin/cysteine -rich domain of ADAM8 mediates cell adhesion in cells 
expressing ADAM8 (17); the “cysteine-rich domain” of ADAM12 promotes the adhesion of 
fibroblasts and myoblasts (30); the disintegrin and cysteine-rich domains of ADAM13 bind to 
both fibronectin and to beta1-containing integrin receptors, and binding can be inhibited by 
antibodies against the cysteine-rich domain (23); the “cysteine-rich domain” of 
TACE/ADAM17 is required for shedding of IL-1R-II while  affecting the inhibitor sensitivity 
of TNF-alpha shedding (31).  
Despite the knowledge about the combined functions of both disintegrin and cysteine -
rich domains, very little information is available about cysteine-rich-domain-specific 
functions. Iba et al. reported that it acts as a ligand for the cell-adhesion molecule syndecan as 
shown for the cysteine -rich domain of ADAM12 (32, 33). Dr. DeSimone‘s group recently 
showed that the cysteine-rich domain of ADAM13 cooperates intramolecularly with the 
metalloproteinase domain of ADAM13 to regulate its function, providing the first evidence 
that a downstream extracellular adhesive domain plays an active role in the regulation of 
ADAM protease function in vivo (26). In this report, we have demonstrated that disulfide 
bonds paired between cysteine residues of N-fragment and one or more cysteine residues at 
C605 , C633 , C639, and C643 within the fraction of the cysteine-rich domain of the C-fragment 
processed at E586-S587of hADAM19 are necessary for the association of the processed N-
fragment with its C-fragment (Fig. 2), and play a critical role in the regulation of hADAM19 
activity by stabilizing the enzyme and preventing its autolysis (Figs. 4, 5, 6, 7). Therefore, we 
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may speculate that these disulfide bonds are very likely to be formed interfragmently between 
the N-fragment, conta ining the metalloproteinase, disintegrin, and part of the cysteine rich 
domain of hADAM19, and the C-fragment, containing the other part of the cysteine-rich 
domain after processed at E586-S587of hADAM19.  Our results provided first pieces of 
evidence in vitro  to support the results of the in vivo  ADAM13 studies discussed above (26), 
and gave a very reasonable explanation for the fact that the processing or shedding of 
hADAM19 occurred autolytically and intramolecularly within its cysteine-rich domain (24; 
Figs. 1, 4B; and data not shown).  
It is possible that the disulfide bonds are formed between the disintegrin domain of 
hADAM19 and this region of the cysteine -rich domain of the C-fragment because the 
disintegrin domain of hADAM19 also plays a key role in  the proteolytic activity of 
hADAM19.  We have previously shown that our specific antibody against the disintegrin 
domain inhibited substrate cleavage in vitro (27), and the deletion mutant containing only the 
metalloproteinase domain of hADAM19 lacked proteolytic activity using alpha 2-M and 
peptide substrate assays in vitro  (data not shown). Any one of four cysteine residues at C605 , 
C633 , C639 , and C643 in the part of cysteine-rich domain is indispensable for the association 
between the N-fragment and C-fragment processed at E586-S587. We presume three disulfide 
bonds may have formed.  One formed between two cysteine residues of C605 , C633 , C639, and 
C643 and two formed by the remaining two cysteine residues paired with two other cysteine 
residues with at least one occurring prior to the position of E586 in the N-fragment.  
Alternatively, four disulfide bonds may exist, formed by C605, C633, C639 , and C643 with four 
other cysteine residues, with at least one being before the position of E586. These bonds ha ve a 
strong coordination with each other, and when one of these disulfide bonds is disrupted, the 
others will be subsequently disturbed. Therefore, we propose that three or four disulfide bonds 
linked by the four cysteine residues at C 605, C633, C639, and C643 with other cysteine residues in 
the N-fragment are responsible for the association between the N -fragment and C-fragment 
   
              
 52 
processed at E586-S587. Currently, we are unable to speculate the identities of these disulfide 
bonds as there are total 43 cysteine residues available in the metalloproteinase, disintegrin, 
cysteine-rich and EGF-like domains of hADAM19.  In the near future, we would like to 
determine the identity of these disulfide bonds using multiple approaches including structural 
biology, analytical chemistry, and biochemical methods.   
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FIGURE LEGENDS 
Figure 1.  Processing at E 586-S587 of hADAM19 occurs intramolecularly. The MDCK cells 
stably expressing soluble inactive hADAM19 (D-E346A) were mixed equally at 24-wells 
with MDCK cells transfected with the blank vector (lane 4), D586 (lane 5), or D -CR (lane 6) 
for 24 hours in serum free media, then the conditioned media were subjected to Western 
blotting with anti-FLAG-M2. The soluble stable lines, D52-5 (lanes 1), D586 (lane 2), or D-
CR (lane 3) alone were as controls. The processed C -fragments of soluble hADAM19 are 
indicated.  
 
Figure 2.  The N -fragments associate with the C-fragments processed at E586-S587 of 
soluble hADAM19 by disulfide bonds.  A) No detection of the processed forms by anti-
FLAG-M2 under non-reducing conditions. The MDCK cells stably expressing soluble 
hADAM19, D52-5 were incubated in serum-free media for 24 hours, then the conditioned 
media was subjected to Western blotting by anti-FLAG-M2 under reducing (lane 2) or non-
reducing conditions (lane 3). The medium from MDCK cells transfected with the blank vector 
was utilized as a control (lane 1). The processed C-fragments of soluble hADAM19 are 
indicated. B) Detection of the processed forms by the specific antibody against the disintegrin 
domain of hADAM19 (Anti-Dis). The same process was performed as A), but using Anti-Dis 
as the probe to detect soluble hADAM19.  The processed N-fragments of soluble hADAM19 
are indicated. C) Any one of the cysteine residues at C605, C633, C639, and C 643 is necessary for 
the association of the processed N-fragment with its C-fragment of soluble hADAM19 in 
COS1 transfected cells. COS1 cells were transfected with blank vector (lanes 1, 7), D52 
(lanes 2, 8), soluble mutants with C605 to S605 (D-C605S, lanes 3, 9), C633 to S633 (D-C633S, 
lanes 4, 10), C639 to S639 (D-C639S, lanes 5, 11), or C643 to S643 (D-C643S, lanes 6, 12), 
followed by incubation for 24 hours in serum -free media. The conditioned media were 
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analyzed by Western blotting with anti-FLAG-M2 under reducing (lanes 1-6) or non-reducing 
conditions (lanes 7-12). The pro- and mature forms, and the processed C -fragments of soluble 
hADAM19 are indicated. Notice: Different profiles are detected for the pro-, mature, and 
processed soluble hADAM19 among these transient transfections, and any one of these Cys to 
Ser mutants induces two processing sites. 
 
Figure 3.  A schematic illustration of the mutants of hADAM19 inse rted in the 
expression vector pCR3.1 . All of the constructs have a C-terminal FLAG tag. SP: Signal 
peptide; Pro-: Prodomain; Cat-: Catalytic domain; Dis -: Disintegrin domain; Cys-: Cysteine-
rich domain; E GF-: EGF-like domain; TM: Transmembrane domain; CD: Cytoplasmic 
domain; F: FLAG tag. 
 
 Figure 4. Different stabilities of soluble of hADAM19 with C to S mutants in stable 
MDCK transfectants. A) Soluble C to S mutants of hADAM19 in stable MDCK 
transfectants have different stabilities. Representative MDCK cells stably expressing D52 
(D52-5, lane 2, 12), D-C633S (D-C633S-4 and D-C633S-5, lanes 3, 4, 13, 14), D-C639S (D-
C639S-8 and D-C639S-10, lanes 5, 6, 15, 16), D-C605S (D-C605S-7 and D-C605S-8, lanes 
7, 8, 17, 18), and D-C643S (D-C643S-6 and D-C643S-9, lanes 9, 10, 19, 20) were seeded in 
equal amounts into different wells of 24-well plates. After reaching 80% confluence, the cells 
were incubated in serum-free media for 24 hours, then the conditioned media (lanes, 1-10) 
and cell lysates (lanes, 11-20) were analyzed by Western blotting using anti-FLAG-M2.  The 
mature forms and the processed C-fragments of soluble hADAM19 are indicated. MDCK 
cells transfected with the blank vector were used as a control. Notice: Different levels of 
mature or processed soluble hADAM19 appear in the media, but not in the cell lysates among 
these transfects. B) The novel processing induced by the mutated cysteine residues is an 
autolysis. The representative MDCK cells stably expressing soluble inactive hADAM19 (D-
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E346A, lane 2), C633 to S633 and E346 to A346 (D-C633S/E346A -7 and D-C633S/E346A-10, 
lanes 3, 4), and C 643 to S 643 and E346 to A346 (D-C643S/E346A-20 and D-C643S/E346A -22, 
lanes 5, 6) were initiated in equal amounts and changed to serum-free media when the cells 
reached 80% confluence. The conditioned media were analyzed by Western blotting using 
anti-FLAG-M2. MDCK cells transfected with the blank vector was used as a control (lane 1). 
Notice: There is no processing at all in the media from the MDCK stable lines of these double 
mutants because the mutants with E346A have no catalytic activity, demonstrating the new 
processing is also autocatalytic. 
 
Figure 5.  The proteins of D-C633S and D586 are more vulnerable to trypsin digestion.  
The conditioned media from MDCK cells stably expressing soluble hADAM19 (D52-5, lanes 
3-7), C633 to S633 (D-C633S-4, lanes 8-12), and D586 (lanes 13-17) were subjected to trypsin 
digestion as described in “Materials and Methods”, with trypsin concentrations at 0 (lanes 3, 
8, 13), 5 (lanes 4, 9, 14), 10 (lanes 5, 10, 15), 20 (lanes 6, 11, 16), 40 (lanes 7, 12, 17) ng/ul, 
and followed by SDS-PAGE and Western blotting with anti-FLAG-M2. The conditioned 
media from MDCK cells transfected with the blank vector were treated without (lane 1) or 
with (lane 2) 40 ng/ul of trypsin and its inhibitors at 2-fold excess of trypsin as controls.   
 
Figure 6. The new processing at K543-V544 induced by mutating the cysteines is 
independent of the normal processing at E586-S 587. A) The independence of the new 
processing in transfected COS1 cells. C OS1 cells were transfected with the blank vector (lane 
1), soluble hADAM19 (D52, lane 2), soluble mutants of hADAM19 with E586 to D 586 (D-
E586D, lane 3), C633 to S633 (D-C633S, lane 4), C633 to S633 and E586 to D 586 (D-C633S/E586D, 
lane 5), C 639 to S639 (D-C639S, lane 6), or C639 to S639 and E 586 to D586 (D-C639S/E586D, lane 
7). After incubation for 24 hours in serum-free media, the  conditioned media were analyzed 
by Western blotting with anti-FLAG-M2. The pro- and mature forms, and the processed C-
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fragments of soluble hADAM19, are indicated. Notice: D -E586D had no processed forms, but 
both D-C633S/E586D and D-C639S/E586D demonstrate the novel processing in the absence 
of normal processing. B) The novel processing induced by the mutated cysteine residues 
occurs independently at K543-V544. The representative MDCK cells stably expressing soluble 
double mutants, C633 to S633 and E586 to D586 (D-C633S/E586D -9 and D-C633S/E586D-13, 
lanes 3, 4), were seeded in equal amounts and changed to serum-free media when the cells 
reached 80% confluence. The conditioned media were analyzed by Western blotting using 
anti-FLAG-M2. MDCK cells transfected with the blank vector (lane 1) and D-C633S-4 (lane 
2) were used as the controls. The sequences for the processed C-terminal proteins are shown 
at the right. Notice: The processing site of K543-V544 is the major one in the media from the 
MDCK cells stably expressing the soluble double mutants of C633S/E586D, while the 
predominant one is E586-S587 in D-C633S. 
 
Figure 7. Shedding of full length hADAM19 with cysteine to serine mutations.  A) The 
shedding status of MDCK cells stably expressing full length mutants of hADAM19. The 
representative MDCK cells stably expressing wild type hADAM19 (F46, lanes 1, 6), or 
mutants with C 633 to S 633 (F-C633S-3 and F-C633S-9, lanes 2, 7, 3, 8), or C643 to S 643 (F -
C643S-4 and F-C643S-7, lanes 4, 9, 5, 10) were seeded at equal amount into different wells 
of 24-well plates, then changed to serum-free media when the cells achieved 80% confluence. 
After 24 hours incubation, the conditioned media (lanes 1-5) and the cell lysates (lanes 6-10) 
were subjected to Western blotting using anti-Dis (lanes 1-5) or anti-FLAG-M2 (lanes 6-10). 
The pro-, mature, and shed forms of hADAM19 are indicated. Notice: F -C633S shed 
significantly, but not F-C643S or F46. B) The regulation of shedding in MDCK cells stably 
expressing F-C633S. MDCK cells stably expressing F-C633S (F-C633S -3) were chosen to 
seed into 24-well plates equally, and the cells were treated with serum-free media alone (lane 
2), or containing GM6001 (2.5 uM, lane 3), PMA (50 ng/ml, lane 4), W7 (100 uM, lane 5) or 
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A23187 (500 nM, lane 6) for 24 hours. The conditioned media were analyzed by Western 
blotting using Anti-Dis. The shed fragments of hADAM19 are indicated. MDCK cells 
transfected with wild type (F46) were used as a control (lane 1). Notice: The shedding F-
C633S was inhibited by A23187 and W7, was little inhibited by GM6001, but was enhanced 
by PMA. 
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4. Discussion 
 
 
4.1 Furin and Metalloproteinases 
 
      The PCs are a large family of serine proteinases, containing PACE(furin), PACE4, 
PC5/PC6, and PC7/PC8, that recognize dibasic motifs and cleave the peptide bond on the 
carboxyl side (Nakayama 1997, Steiner 1998, Molloy et al. 1999). As a major PC, furin is 
concentrated in the trans-Golgi network (TGN) and cycles between this compartment and the 
cell surface through the endocytic pathway. The autoactivation and intracellular trafficking of 
furin are well characterized.  Numerous studies have shown that furin activates a large 
number of proproteins in multiple compartments (Nakayama 1997, Steiner 1998, Molloy et al. 
1999). The minimal recognition sequence for furin requires basic residues at P1 and P4, but the 
efficient cleavage by furin is RXK/RR, and in some cases, at the P1’ position, an amino acid 
with a hydrophobic aliphatic side chain is not suitable (Nakayama 1997). The initial 
demonstration that furin is responsible for activation of metalloproteinases was shown in 
MMP11 (Pei and Weiss, 1995), and this mechanism was extended to some other MMPs, such 
as MMP14, 16, 24, and many ADAMs, including ADAM1, 9, 12, 15, 17 and 19 and ADAM-
TS1, 4, 9, and 12 (Lum and Blobel 1997, Lum et al. 1998, Loechel et al. 1998, Kuno et al. 
1999,  Roghani et al. 1999, Schlondorff et al. 2000,  Yana and Weiss 2000, Wang and Pei 
2001, Cal et al. 2001, 2002, Guo et al. 2002, Cao et al. 2002, Kang et al. 2002a, 2002b, 
Somerville et al., 2003).  Typically, there is only one furin recognition site between the  pro- 
and catalytic- domain  of metalloproteinases in most cases (Pei and Weiss 1995, Black et al. 
1997, Moss et al. 1997, Nakayama 1997, Tortorella et al. 1999, Molloy et al. 1999, Stone et 
al, 1999, Primakoff and Myles 2000, Yana and Weiss 2000, Vu and Werb 2000, Yoshinaka et 
al. 2002, Kang et al. 2002a ). I presented evidence for the first time that there are two 
consecutive functional furin recognition sites, R197PRR200 and R200MKR203 , which adhere to 
the rules for efficient cleavage by furin (Nakayama 1997), between the  pro- and catalytic-
domain in hADAM19 (Kang et al. 2002b) .  However, N-terminal sequencing of wild type 
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mature forms confirmed that the primary intracellular cleavage site for hADAM19 activation 
is the one nearer to the catalytic domain , R200MKR203 as predicted before, and this motif is 
conserved in mice as R201MKR204 (Fritsche et al. 2000, Wei et al. 2001, Kang et al. 2002b). 
On the other hand, the farther one, R197PRR200 in humans, which was functional when the 
primary site was abolished (Kang et al. 2002b) , is replaced with Q198PRR201 in mice (Inoue et 
al. 1998, Kurohara et al. 2000) , which is not efficiently cleaved by furin. It is noticeable that 
there are also two potentially consecutive alternative furin recognition sites in other 
metalloproteinase zymogens, including ADAM11 (AB009675, R292LRRKR297), ADAM22 
(AF 155382, R219PKRSKR205), ADAM-TS4 (AF148213, R206PRRAKR212), ADAM-TS9 
(AA205581, R280TRRRTKR287), MT2-MMP (NM_002428, R126RRRKR131), and MT5-MMP 
(AJ010262, R118RRRNKR224). The ones nearer to the catalytic domains are conserved in 
different species, whereas the farther ones might be related to evolution. Although the 
significance of the two alternative recognition sites in these precursors remains poorly 
understood, I may speculate that the processing of these zymogens are crucial for some 
biological events ; the zymogens will be activated by fur in at a different site when the primary 
site is abrogated.  Moreover, I provided evidence for the first time that furin was co-localized 
with both ADAM19 and MMP16 in the ER/Golgi complex and/or TGN, which were 
independent of their apparent enzyme-substrate relationship, demonstrating that some 
ADAMs and MMPs are physiologically relevent substrates activated  by furin (Kang et al. 
2002a, 2002b) .  
 
4.2 Shedding of Metalloproteinases.  
      Increasing evidence suggests that shedding is of vital importance for the regulation of 
metalloproteinase activity. For MT-MMPs, Dr. Pei´s group reported that MT5-MMP is shed 
by furin, down-regulating its activity, and that interleukin-8 triggers the signal for both release 
and activation of MT6-MMP by an unknown mechanism (Wang and Pei 2001, Kang et al. 
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2001). The activity of MT1-MMP can be autolytically terminated directly on the cell surface 
or via production of a soluble functional fragment, consequently down-regulating enzyme 
activity on the cell surface (Toth et al. 2002). Among ADAMs, ADAM13 and ADAM19 have 
been shown to shed or processed intracellularly by an autolytic mechanism, producing an 
active enzyme able to bind with alpha2-M and integrins (Gaultier et al. 2002), or cleave both 
alpha2-M and a peptide substrate in vitro (Kang et al 2002c, submitted), and ADAM8 was 
shown to be further autolytically processed to separate its metalloproteinase domain, which 
was active against MBP, from its disintegrin and cysteine-rich (DC) domains after the 
autolytic removal of its prodomain, subsquently, the DC domains mediate cell ahesion by 
dimerizing through the homophilic interaction (Schlomann et al. 2002). In addition, truncation 
of mature ADAM-TS4 at its C-terminus is required for its aggrecanase activity (Guo et al. 
2002). It might, therefore, be a general regulatory mechanism that MT-MMPs, such as MT1-
MMP and MT5-MMP, are down-regulated by shedding to release active forms from the cell 
surface, whereas ADAMs have to be shed, processed or truncated at the C-terminus to exert 
their functions, such as acting as a sheddase, binding with integrins, or forming homophilic 
dimer on the cell surface, or digesting components of the extracellular matrix. For the 
significance of autolytic processing or shedding in hADAM19, I have demonstrated that 
hADAM19 processing or shedding occ urs at a different position removed from the normal 
processing site at E586-S587 under certain conditions, as in the case of the disruption of 
disulfide bonds by mutation or reduction. This also produces an active enzyme, suggesting 
that there is an alternative site for the processing or shedding of hADAM19 within the 
cysteine-rich domain to achieve fully activated hADAM19, indicative of its very important 
roles in both physiological and pathological conditions (Kang et al. 2002b, 2002c, and 
submitted) 
       However, the signal pathways involved in shedding processes, especially of ADAMs, are 
poorly understood. In this dissertation (Kang et al., 2002c, submitted), I provided unique 
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characteristics of the regulation of hADAM19 processing or shedding within its cysteine-rich 
domain, which are distinguishable from those shown for other ADAMs, MT-MMPs, and 
other membrane-bound proteins. I found that PMA, a common inducer of shedding, also 
enhances the processing or shedding of hADAM19, and this probably involves the 
cytoplasmic domain, transmembrane domain, or both. This is consistent with the reports 
showing that the cytoplasmic domain of ADAM9 is required for PMA-induced shedding 
(Izumi et al. 1998), and that the membrane anchor of TACE is necessary for its processing of 
TNF-alpha (Reddy et al. 2000, Itai et al. 2001). However, in most cases, endogenous and/or 
inducer-mediated shedding is independent of the cytoplasmic domain (Crowe et al. 1995, 
Dethlefsen et al. 1998, Kahn et al. 1998, Vecchi et al. 1998, Diaz-Rodriguez et al. 2000). 
Calcium ionophore, A23187, and the inhibitors of Calmodulin (CaM) are also potent inducers 
of many protein shedding processes (Pandiella and Massague 1991, Yee et al. 1993, Vecchi et 
al. 1996, Dethlefsen et al. 1998, Kahn et al. 1998, Diaz-Rodriguez et al. 2000, Annabi et al. 
2001, Fors et al. 2001). Nevertheless, I found that A23187 and inhibitors of CaM block or 
impair the processing or shedding of hADAM19. On the other hand, I revealed that neither 
tyrosine kinase, MAP kinase, phosphatase, nor PI-3K seemed to play roles in the processing 
of hADAM19, although they have been shown to participate in some shedding processes in 
the past (Desdouits-Magnen et al. 1998, Vecchi et al. 1998, Fan and Derynck 1999, Gechtman 
et al. 1999, Gutwein et al. 2000, Schlondorff  et al. 2001, Nath et al. 2001).  
        In addition, the proteinases responsible for the shedding of many cell surface molecules 
seem to have broad sequence specificity as revealed by mutational analysis of residues around 
the cleavage site of pro-TGFalpha , APP, IL-6 receptor, L -selectin, and pro-TNFalpha (Wong 
et al. 1989, Sisodia 1992, Müllberg et al. 1994, Migaki et al. 1995, Tang et al. 1996). I used 
mutagenesis to show that the size of residues at both the E586 and S587 sites, especially the size 
of the side-chains, are extremely important for normal processing of hADAM19. Even 
delicate changes, such as E586 to D586 and S587 to T587, caused dramatic decreases in the 
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processing (Kang et al. 2002c). Intriguingly, many studies have shown that some potent 
synthetic inhibitors of metalloproteinases, such as TAPI, BB94, and GM6001, can block 
most, if not all, shedding processes, and that many shedding processes are sensitive to TIMP3, 
a matrix-associated TIMP that preferably inhibits ADAMs (Crowe et al. 1995, Arribas et al. 
1996, 1997, Hooper et al. 1997, Mullberg et al. 1997, Peschon et al. 1998, Hargreaves et al. 
1998, Borland et al. 1999, Fitzgerald et al. 2000, Diaz-Rodriguez et al. 2000, Ilan et al. 2001, 
Nath et al. 2001, Bailly et al. 2002). However, neither GM6001 nor TIMP3 inhibits the 
processing or shedding of hADAM19, which is consistent with some reports showing that the 
shedding of MT5-MMP, MT6-MMP, and IL -6 receptor is not affected by metalloproteinase 
inhibitors (Müllberg et al. 1995, Wang and Pei 2001, Kang et al. 2001). Nevertheless, both 
GM6001 and TIMP3 are able to dramatically inhibit the activity of soluble hADAM19 
against our peptide substrate in vitro (data not shown). One possibility, we speculate, is that 
shedding, in most cases, occurs at membrane-proximal regions on the cell surface, which are 
easily accessible to hydroxamate -based inhibitors and TIMP3 (Migaki et al. 1995, Arribas et 
al. 1997, Hooper et al. 1997, Alfalah et al. 2001). hADAM19 carries out the processing or 
shedding at a region distal from the transmembrane domain in the secretory pathway, which is 
less accessible to GM6001 and TIMP3 (Kang et al. 2002c, submitted).  
  
4.3 Regulations and Functions of ADAM19.    
        Adamalysin 19/ADAM 19/ MDC19/meltrin beta, cloned from mice and human, is a type 
I membrane-bound protein containing the fundamental domains of ADAMs, such as the 
prodomain, metalloprotease and disintegrin domains, cysteine-rich domain, EGF-like domain, 
transmembrane domain, and cytoplasmic domain (Inoue et al. 1998, Stone et al. 1999, 
Primakoff and Myles 2000, Kurohara et al. 2000, Fritsche et al. 2000, Wei et al. 2001). 
Synthesized as a zymogen in the ER, hADAM19 is cleaved by furin to remove its prodomain, 
and is then processed at    E586-S587 within the cysteine-rich domain by autolysis in the TGN 
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(Kang et al. 2002b, 2002c). This produces an active N-terminal fragment, which contains 
metalloproteinase and disintegrin domains and part of the cysteine-rich domain to exert its 
sheddase activity such as releasing beta type-NRG in the TGN (Shirakabe et al., 2001). 
Alternatively, the active N-terminal fragment is transported to cell surface, where it acts as a 
sheddase (Shirakabe et al., 2001) or binds with components in the ECM. Because proforms of 
hADAM19 exhibit no changes under reducing or non-reducing conditions (Kang et al. 
submitted), I may also propose that hADAM19 forms dimers, tetramers or higher multimers 
after prodomain cleavage and/or autolytic truncation at the cysteine -rich domain (Kang et al. 
submitted), probably through the metalloproteinase domain, in which there are 7 (an odd 
number) cysteine residues, as this domain is also able to form dimers, tetramers or higher 
multimers (data not shown), which then function in secretory pathways or on the cell surface. 
However, the pro- and mature- forms of hADAM19 without processing within its cysteine-
rich domain might also be partially transported to cell surface as shown in other ADAMs, 
such as ADAM9, 12, 15, 17 (Loechel et al. 1998, Lum et al. 1998, Roghani et al. 1999, 
Schlondorff et al. 2000, Cao et al 2002). 
        Regarding the role of cysteine-rich domain in the activation and processing of 
hADAM19, the “cysteine-rich domain” is sometimes referred to the cysteine-rich domain 
together with the disintegrin domain. In these cases, the “cysteine-rich domain” has been 
shown to be related to cell adhesion, such as in the cases of ADAM8, 12, 13, or to the 
proteolytic activity of TACE/ADAM17. For example, the recombinant disintegrin/cysteine-
rich domain of ADAM8 mediates cell adhesion in cells expressing ADAM8 (Schlomann et al. 
2002). The “cysteine-rich domain” of ADAM12 promotes the adhesion of fibroblasts and 
myoblasts (Zolkiewka  1999). The disintegrin and cysteine-rich domains of ADAM13 bind to 
both fibronectin and beta1-containing integrin receptors, and binding can be inhibited by 
antibodies against the cysteine-rich domain (Gaultier et al. 2002). The “cysteine -rich domain” 
of TACE/ADAM17 is required for shedding of IL-1R-II while  affecting the inhibitor 
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sensitivity of TNF shedding (Reddy et al. 2000). However, for cysteine-rich-domain-specific 
functions, there is little information available; Iba et al. reported that it acts as a ligand for the 
cell-adhesion molecule syndecan as shown for the cysteine-rich domain of ADAM12 (Iba et 
al. 1999, 2000, Thodeti et al., 2003). Dr. DeSimone’s group recently showed that the cysteine-
rich domain of ADAM13 cooperates intramolecularly with the metalloproteinase domain of 
ADAM13 to regulate its function, providing the first evidence that a downstream extracellular 
adhesive domain plays an active role in the regulation of ADAM protease function in vivo  
(Smith et al. 2002). In this dissertation, I have demonstrated that disulfide bonds paired with 
the cysteine residues at C605, C633, C639, or C643 within the fraction of the cysteine-rich domain 
of the C-terminal fragment processed at E586-S587 of hADAM19 are necessary for the 
association of the processed N-terminal with its C -terminal fragments, and play a critical role 
in the regulation of hADAM19 activity by stabilizing the enzyme and/or preventing its 
autolysis (Kang et al. submitted). Therefore, it is very likely that these disulfide bonds form 
intramolecularly between the metalloproteinase domain of hADAM19 and the part of the 
cysteine-rich domain of the C-terminal fragment processed at E586-S587 of hADAM19. If this 
is the case, I provide the first evidence in vitro to support the results of the in vivo ADAM13 
studies (Smith et al. 2002), and give a very reasonable explanation for the fact that the 
processing or shedding of hADAM19 occurs autolytically and intramolecularly within its 
cysteine-rich domain (Kang et al. 2002c , submitted). However, I am unable to rule out the 
possibility of the formation of disulfide bonds between the disintegrin domain of hADAM19 
and this region of the cysteine -rich domain, because the disintegrin domain of hADAM19 
also plays a key role in the proteolytic activity of hADAM19, as shown by specific antibody 
blocking assays in vitro (Zhao et al. 2001), and by the lack of proteolytic activity using 
alpha2-M and peptide substrate assays in vitro for the deletion mutant containing only the 
metalloproteinase domain of hADAM19 (data not shown). Any one of four cysteine residues 
at C605 , C633 , C639, and C643 in the segment of cysteine-rich domain is indispensable for the 
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association between the N-terminal and C-terminal fragments processed at E586-S587. I 
presume three disulfide bonds, one formed between two cysteine residues of C605, C633, C639 , 
or C643 and two formed by the remaining cysteine residues paired with two other cysteine 
residues, with at least one occurring prior to the position of E586. Alternatively, four disulfide 
bonds may exist, formed by C 605, C633, C639, and C643 with four other cysteine residues, with 
at least one being before the position of E586. These bonds have a strong coordination with 
each other, and when one of these disulfide bonds is disrupted, the others will be subsequently 
disturbed. Therefore, I propose that three or four disulfide bonds linked by the four cysteine 
residues at C605, C633, C639, and C643 are responsible for the association between the N -
terminal and C-terminal fragments processed at E 586-S587. However, I am currently limited to 
identify these four cysteine residue pairs, as there are total 43 cysteine residues available in 
the metalloproteinase, disintegrin, cysteine -rich and EGF-like domains of hADAM19.  
       With regard to the signal pathways related to the activation and the processing of 
hADAM19, I demonstrated in this dissertation that calcium signal is related to both the 
removal of the prodomain in ADAM19 by furin and the antolytic processing or shedding of 
hADAM19, and that both PKC and CaM signal pathways are involved in the processing or 
shedding of hADAM19 (Kang et al. 2002b, 2002c, submitted). However, for the processed C-
terminal remnant, containing a fraction of the cysteine-rich domain, transmembrane domain 
and cytoplasmic domain, persumably localized on cell surface, its potential functions related 
to the signals remain to be uncovered, because two SH3 binding sites exist in its cytoplasmic 
domain. Interestingly, a meltrin beta mini, lacking the prodomain, metalloproteinase and 
disintegrin domains, was recently reported, in which show ed that this novel meltrin beta 
isoform induced neurite outgrowth in neuronal cells (Kurisaki et al. 2002). Huang et al. 
showed that ADAM19 cytoplasmic tail specifically interacts with ArgBP1, beta-cop, 
ubiquitin and another unknown protein by a yeast two-hybrid screening (Huang et al. 2002). 
In addition, hADAM19 is an important marker for the differentiation and characterization of 
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dendritic cells and the distinction between macrophages and dendritic cells (Fritsche et al. 
2000). But the mechanism for this function is unknown.  
        Regarding the proteolytic activity of ADAM19, soluble hADAM19 is able to form 
complex with alpha 2-M and generate two products in vitro, which can be blocked by the 
antibodies against its metalloproteinase domain and disintegrin domain, but not its 
prodomain, suggesting that the disintegrin of ADAM19 play a critical role in its proteolytic 
activity (Wei et al. 2001, Zhao et al. 2002, Kang et al. 2002b, 2002c). In this dissertation, I 
developed a peptide substrate, Ac-RPLESNAV, which can also be cleaved by soluble 
hADAM19 in vitro  (Kang et al. 2002b, 2002c). My preliminary data show that TIMP3 can 
inhibit hADAM19 activity in this assay (data not shwon), which is similar to the results with 
ADAM10, 12, 17, and ADAM-TS4 and 5 in vitro  (Amour et al. 1998, 2000, Loechel et al. 
2000, Kashiwagi et al. 2001). Interestingly, ADAM-TS4 is truncated at E373-A374, the site for 
the cleavage of ADAM-TS4 and ADAM-TS5, but not MMPs. In contrast, the truncation site 
at N341-F342 is mediated by MMPs, but not aggrecanases (Guo et al. 2002, Westling et al. 
2002). Our mutational data showed that the E586-A587 shedding site was also optimal for 
autolytic processing of hADAM19, indicating that our peptide substrates might be useful to 
determine the activity of other ADAMs, such as aggrecanases, ADAM-TS4 and 5. In this 
way, it is possible for us to establish unique inhibitor profiles for individual ADAMs. On the 
other hand, ADAM19 might be one of the aggrecanases to cleave aggrecan at at E373-A374, 
versican at E441-A442, and/or brevican at E395-A396, albeit the direct evidence remains to be 
provided. In an overall review, it is believable that ADAM19/meltrin beta/MDC19 may play a 
crucial role in osteoblast differentiation, early heart and central nervous system development, 
angiogenesis, rheumatoid arthritis and glioma. 
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6. Abbreviations  
 
 
Ab, antibody; ADAM, a disintegrin and metalloproteinase; ADAMTS, a disintegrin and 
metalloproteinase with thrombospondin-like motifs; alpha2-M, alpha-2-macroglobulin; APP, 
amyloid precursor protein; ArgBP1, Arg binding protein 1; BACE, beta -amyloid converting 
enzyme; BCIP, 5-bromo-4-chloro-3-indoyl phosphate; beta -cop, beta -subunit of Coatomer 
protein; BFA, brefeldin A; CaM, calmodulin; CLM, calmidazolium; decRVKR-CMK, 
decanoyl-Arg-Val-Lys-Arg-chloromethylketone; DMEM, Dulbecco’s modified Eagle´s 
medium; ECM, extracellular matrix; EDTA, ethylenediaminetetraacetic acid; EGF, epidermal 
growth factor; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; FBS, 
fetal bovine serum; GPCRs, G-protein-coupled receptors; MAP kinase, mitogen-activated 
protein kinase; MBP, myelin basic protein, MDC, Metalloprotease/Disintegrin/Cysteine-rich; 
MDCK, Madin-Darby canine kidney; MMPs, matrix metalloproteinases; MT-MMPs, 
membrane-type matrix metalloproteinases;  NBT, nitro blue tetrazolium; NRG, neuregulin; 
pAT, alpha1-antitrypsin or alpha1-proteinase inhibitor (alpha-PI); pATp, Pittsburgh mutant of 
alpha-1 antitrypsin/proteinase inhibitor (alpha1-Pipitt or alpha1-PIp ); PACE4, paired basic 
amino acid converting enzyme 4; PBS, phosphate buffered saline; PC, proprotein convertase; 
7.P15 cells, furin -deficient monkey kidney COS-7 strain cells; P I-3K, phosphatidylinositol-3 
kinase; PKC, protein kinase C ; PMA, phorbol-12 myristate 13-acetate; RPE.40 cells, furin-
deficient Chinese hamster ovary (CHO)-K1 strain cells; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis; TACE, tumor necrosis factor a  convertase; TAPI, tumor 
necrosis factor-?  proteinase inhibitor; TFP, trifluoperazine; TIMPs, tissue inhibitors of 
metalloproteinases; TGF-alpha, transforming growth factor -alpha? TNF-alpha, tumor necrosis 
factor-alpha; TRANCE, TNF-related activation-induced cytokine; W7, N-(6-aminohexyl)-5-
chloro-1-naphthalenesulfonamide.    
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